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Background: Tranexamic acid reduces blood loss in surgery and the risk of death in trauma patients.
Meta-analyses of small trials suggest that tranexamic acid decreases the number of deaths from
gastrointestinal bleeding, but these meta-analyses are prone to selection bias.
Objective: The trial provides reliable evidence of the effect of tranexamic acid on mortality, rebleeding
and complications in significant acute gastrointestinal bleeding.
Design: A multicentre, randomised, placebo-controlled trial and economic analysis. Patients were
assigned by selecting one treatment pack from a box of eight, which were identical apart from the pack
number. Patients, caregivers and outcome assessors were masked to allocation. The main analyses
were by intention to treat.
Setting: The setting was 164 hospitals in 15 countries, co-ordinated from the London School of
Hygiene & Tropical Medicine.
Participants: Adults with significant upper or lower gastrointestinal bleeding (n = 12,009) were eligible
if the responsible clinician was substantially uncertain about whether or not to use tranexamic acid.
The clinical diagnosis of significant bleeding implied a risk of bleeding to death, including hypotension,
tachycardia or signs of shock, or urgent transfusion, endoscopy or surgery.
Intervention: Tranexamic acid (a 1-g loading dose over 10 minutes, then a 3-g maintenance dose over
24 hours) or matching placebo.
Main outcome measures: The primary outcome was death due to bleeding within 5 days of
randomisation. Secondary outcomes were all-cause and cause-specific mortality; rebleeding; need for
endoscopy, surgery or radiological intervention; blood product transfusion; complications; disability;
and days spent in intensive care or a high-dependency unit.
Results: A total of 12,009 patients were allocated to receive tranexamic acid (n = 5994, 49.9%) or the
matching placebo (n = 6015, 50.1%), of whom 11,952 (99.5%) received the first dose. Death due to
bleeding within 5 days of randomisation occurred in 222 (3.7%) patients in the tranexamic acid group
and in 226 (3.8%) patients in the placebo group (risk ratio 0.99, 95% confidence interval 0.82 to 1.18).
Thromboembolic events occurred in 86 (1.4%) patients in the tranexamic acid group and 72 (1.2%)
patients in the placebo group (risk ratio 1.20, 95% confidence interval 0.88 to 1.64). The risk of arterial
thromboembolic events (myocardial infarction or stroke) was similar in both groups (0.7% in the
tranexamic acid group vs. 0.8% in the placebo group; risk ratio 0.92, 95% confidence interval 0.60 to
1.39), but the risk of venous thromboembolic events (deep-vein thrombosis or pulmonary embolism)
was higher in tranexamic acid-treated patients than in placebo-treated patients (0.8% vs. 0.4%; risk
ratio 1.85, 95% confidence interval 1.15 to 2.98). Seizures occurred in 38 patients who received
tranexamic acid and in 22 patients who received placebo (0.6% vs. 0.4%, respectively; risk ratio 1.73,
95% confidence interval 1.03 to 2.93). In the base-case economic analysis, tranexamic acid was not
cost-effective and resulted in slightly poorer health outcomes than no tranexamic acid.
Conclusions: Tranexamic acid did not reduce death from gastrointestinal bleeding and, although
inexpensive, it is not cost-effective in adults with acute gastrointestinal bleeding.
Future work: These results caution against a uniform approach to the management of patients
with major haemorrhage and highlight the need for randomised trials targeted at specific
pathophysiological processes.
Limitations: Although this is one of the largest randomised trials in gastrointestinal bleeding, we
cannot rule out a modest increase or decrease in death due to bleeding with tranexamic acid.
Trial registration: Current Controlled Trials ISRCTN11225767, ClinicalTrials.gov NCT01658124 and
EudraCT 2012-003192-19.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 58. See the NIHR Journals Library website for further project information.
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Acute gastrointestinal bleeding (bleeding from the gut) is a common emergency and an importantcause of death and illness worldwide. In the UK, more than 65,000 people each year are admitted
to hospital because of acute gastrointestinal bleeding; approximately 10% of them die within 30 days.
Gastrointestinal bleeding is also common in low- and middle-income countries. The care of patients
with gastrointestinal bleeding has improved in recent decades, but death rates remain high. Gastrointestinal
bleeding is often caused by stomach ulcers, but also by liver damage owing to alcohol or hepatitis C
infection. An effective and affordable treatment for gastrointestinal bleeding could save many lives and
may reduce the need for blood transfusions, which is important because blood is a scarce resource in
some health-care settings.
Tranexamic acid, also known as TXA, is a cheap drug that reduces bleeding in other conditions. It helps
blood to clot, thereby decreasing bleeding. A trial in bleeding accident victims found that tranexamic
acid reduced the chances of bleeding to death, without any increase in side effects. We wanted to find
out if tranexamic acid safely improves outcomes in patients with gastrointestinal bleeding, particularly
to prevent deaths.
To investigate this, the HALT-IT (Haemorrhage ALleviation with Tranexamic acid – Intestinal system) trial
studied 12,009 patients with significant gastrointestinal bleeding in 164 hospitals across 15 countries.
Half of the patients received tranexamic acid and the other half received a dummy drug, called a placebo.
The treatments were assigned randomly and given in addition to all other treatments needed. Neither
the patient nor the doctor knew which treatment a patient received.
The trial showed that tranexamic acid did not reduce deaths from gastrointestinal bleeding. Instead,
tranexamic acid was linked to an increased risk of complications, including unwanted blood clots
(such as deep-vein thrombosis) and seizures. The economic analysis indicated that giving tranexamic
acid to patients with gastrointestinal bleeding does not represent value for money for the NHS.
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Tranexamic acid reduces blood loss in surgery and death in trauma patients. Meta-analyses of small
trials show that tranexamic acid may decrease the number of deaths from gastrointestinal bleeding.
However, meta-analyses of small trials are prone to selection bias and have a low positive predictive
value compared with results from large trials.
Objectives
We assessed the effects of tranexamic acid on the occurence of death, rebleeding and complications in
acute gastrointestinal bleeding.
Methods
In an international, multicentre, randomised, placebo-controlled trial, adults with significant upper or
lower gastrointestinal bleeding were randomly assigned to receive tranexamic acid (1-g loading dose
followed by a 3-g maintenance dose over 24 hours) or a matching placebo. Patients were assigned
by selecting a numbered treatment pack from a box containing eight packs that were identical apart
from the pack number. Patients, caregivers and those assessing outcomes were masked to allocation.
The primary outcome was death due to bleeding within 5 days of randomisation. Secondary outcomes
were cause-specific and all-cause mortality; rebleeding; surgical or radiological intervention; blood
transfusion; thromboembolic events (deep-vein thrombosis, pulmonary embolism, stroke, myocardial
infarction); seizures; and other complications.
Results
Between July 2013 and June 2019, we randomly allocated 12,009 patients from 164 hospitals in
15 countries to receive tranexamic acid (n = 5994; 49.9%) or matching placebo (n = 6015; 50.1%),
of whom 11,952 (99.5%) received the first dose of the allocated treatment.
Primary outcome
Death due to bleeding within 5 days of randomisation occurred in 222 out of 5956 patients (4%) in
the tranexamic acid group and in 226 out of 5981 patients (4%) in the placebo group (risk ratio 0.99,
95% confidence interval 0.82 to 1.18).
Secondary outcomes
Fatal or non-fatal thromboembolic events occurred in 86 (1.4%) patients in the tranexamic acid group
and 72 (1.2%) patients in the placebo group (risk ratio 1.20, 95% confidence interval 0.88 to 1.64).
The risk of arterial thromboembolic events (myocardial infarction or stroke) was similar in tranexamic
acid- and placebo-treated patients (0.7% vs. 0.8%; risk ratio 0.92, 95% confidence interval 0.60 to 1.39),
but the risk of venous thromboembolic events (deep-vein thrombosis or pulmonary embolism) was
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higher in tranexamic acid-treated patients than in placebo-treated patients (0.8% vs. 0.4%; risk ratio 1.85,
95% confidence interval 1.15 to 2.98). Seizures occurred in 38 patients who received tranexamic acid and
in 22 patients who received placebo (0.6% vs. 0.4%; risk ratio 1.73, 95% confidence interval 1.03 to 2.93).
The effect of tranexamic acid on death due to bleeding within 5 days of randomisation did not appear
to vary when stratified by country income, anticoagulant use or systolic blood pressure in an analysis
that was not prespecified.
Death due to bleeding within 24 hours of randomisation occurred in 124 (2.1%) patients in the
tranexamic acid group and in 120 (2.0%) patients in the placebo group (risk ratio 1.04, 95% confidence
interval 0.81 to 1.33). Death due to bleeding within 28 days of randomisation occurred in 253 (4.2%)
patients in the tranexamic acid group and in 262 (4.4%) patients in the placebo group (risk ratio 0.97,
95% confidence interval 0.82 to 1.15). Death from all causes within 28 days of randomisation occurred
in 564 patients (9.5%) in the tranexamic acid group and in 548 patients (9.2%) in the placebo group
(risk ratio 1.03, 95% confidence interval 0.92 to 1.16).
The proportion of patients with rebleeding was similar in both groups at 24 hours, 5 days and 28 days
after randomisation.
The proportion of patients who had surgery, radiological intervention and blood product transfusion
was also similar in both groups.
The results from the economic analysis suggest that the costs and outcomes of treating people with
acute gastrointestinal bleeding with and without tranexamic acid are very similar, with no tranexamic
acid being more likely to be the most cost-effective option.
Conclusion
In this trial, tranexamic acid did not reduce death from gastrointestinal bleeding but was associated with
an increased risk of venous thromboembolic events and seizures. Therefore, although it is inexpensive,
tranexamic acid does not represent value for money in adults with acute gastrointestinal bleeding.
Implications for practice
Many emergency physicians and surgeons believe that tranexamic acid improves outcomes in patients
with acute severe gastrointestinal bleeding. The promotion of ‘major haemorrhage protocols’ in UK
hospitals encourages the notion that all bleeding is fundamentally the same and can be treated in a
similar way. Furthermore, the Cochrane systematic review and meta-analysis of previous trials of
tranexamic acid in gastrointestinal bleeding shows a large reduction in mortality with tranexamic acid
(pooled risk ratio 0.61, 95% confidence interval 0.42 to 0.89; p= 0.01) (Gluud LL, Klingenberg SL, Langholz E.
Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012;1:CD006640).
The results from the HALT-IT (Haemorrhage ALleviation with Tranexamic acid – Intestinal system) trial
caution against a ‘one size fits all’ approach to the management of patients with major haemorrhage,
and highlight the need for randomised trials targeted at specific pathophysiological processes. Based
on the HALT-IT trial results, tranexamic acid should not be used for the treatment of gastrointestinal
bleeding outside the context of a randomised trial.
Because gastrointestinal bleeding is a licensed indication for tranexamic acid, our results could have
regulatory implications.
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Recommendations for future research
Although we cannot rule out a modest increase or decrease in death due to bleeding with tranexamic
acid, we can rule out the large mortality reduction suggested by the Cochrane systematic review
and meta-analysis of previous small trials (Gluud, et al. 2012). In this respect, the HALT-IT trial
highlights the dangers of overinterpreting results from systematic reviews of small trials.
The large discrepancy between the results of the Cochrane review (Gluud, et al. 2012) and the results of
the HALT-IT trial should encourage a reconsideration of the role of systematic reviews of small trials in
informing health care and health research. In most cases, the results of such reviews should be considered
hypothesis generating, requiring confirmation in adequately powered randomised trials.
Because tranexamic acid reduces bleeding deaths in patients with traumatic and post-partum
haemorrhage, individual patient data meta-analyses should assess the strength of the evidence that the
effectiveness and safety of tranexamic acid varies by the site and cause of bleeding. Basic research
could also inform this question by examining the role of fibrinolysis in patients with gastrointestinal
bleeding and whether or not this varies depending on the aetiology of the bleeding.
A large proportion of patients in this trial had liver disease (40%), so future research could also assess
the effect of tranexamic acid on bleeding from peptic ulcers in patients without liver disease.
Trial registration
This trial is registered as ISRCTN11225767, ClinicalTrials.gov NCT01658124 and EudraCT
2012-003192-19.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 58.
See the NIHR Journals Library website for further project information.
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Acute gastrointestinal bleeding (AGIB) is a common emergency and an important cause of death
worldwide.4 Bleeding can occur from the upper or lower gastrointestinal (GI) tract, but upper GI
bleeding is more common. Symptoms of GI bleeding include haematemesis and coffee ground vomitus,
melaena and the passage of fresh red blood in the stool, and clinical signs of shock, such as hypotension
and tachycardia. Despite evidence suggesting improvements in survival in recent decades, the case
fatality rate is about 10% for upper GI bleeding and 3% for lower GI bleeding.5,6 However, mortality in
patients with lower GI bleeding increases to about 20% in patients who are admitted to hospital for
other reasons and have a GI bleed.7 Most cases occur in the elderly and many are associated with the
use of non-steroidal anti-inflammatory drugs (NSAIDs).8,9
Prevalence of gastrointestinal bleeding
The incidence of GI bleeding varies widely between countries, depending on the population prevalence
of risk factors, with a reported incidence of upper GI bleeding of 50–140 per 100,000 people across the
USA, Europe and Scandinavia.10–18 In the UK, acute upper GI bleeding accounts for about 60,000 hospital
admissions each year and causes the death of about 10% of these patients.5,10 Lower GI bleeding accounts
for a further 15,000 UK admissions each year, with a case fatality of about 15%. GI bleeding is also
common in low- and middle-income countries, where patients are usually young and poor.
Causes of gastrointestinal bleeding
The leading causes of upper GI bleeding are peptic ulcer, oesophageal varices and erosive mucosal disease.
Peptic ulcer disease and erosions due to Helicobacter pylori infection and NSAID use are common causes
of GI bleeding worldwide.4,5,10,15,19–24 Leading causes of lower GI bleeding are diverticular disease, colitis
and cancer.25 Common causes of acute upper GI bleeding in high-income countries are ulcers (40%) and
oesophageal varices (11%).5 Although gastro-oesophageal varices due to liver cirrhosis are an increasingly
common cause of bleeding in the West, they are also a major cause of bleeding in parts of South America,
Asia, Africa and the Middle East, where there is high prevalence of hepatitis or schistosomiasis.26–33
In low- and middle-income countries, variceal bleeding is particularly common (45%), with peptic ulcers
accounting for about 30% of cases. In sub-Saharan Africa, schistosomiasis is an important cause of portal
hypertension, responsible for about 130,000 deaths from haematemesis each year.34 Despite advances
in the management of upper GI bleeding in the past two decades, mortality remains high. In a
nationwide UK study, the case fatality for new presentations to hospital was 7%, rising to > 26% in
patients already hospitalised for another condition.5,35 In addition to cause of bleeding, other factors
associated with mortality include older age, signs of shock, severe bleeding, active bleeding, rebleeding
and extent of comorbid disease.4,36–39
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Rebleeding
Some patients with GI bleeding initially stop bleeding and have a brief period of haemodynamic
stability before starting to bleed again. This phenomenon, known as rebleeding, is common and can
affect between 5% and 40% of patients with acute GI bleeding. Rebleeding is a strong predictor of
mortality in patients with GI bleeding and is associated with a four-fold increased risk of death.5,6,36,37,40
The risk of rebleeding is highest in the days immediately after the index bleed and declines rapidly
with time.41–43 A study in patients with bleeding peptic ulcers44 found that more than half of the
rebleeds occurred in the 24 hours after initial treatment. Rebleeding rates have not changed significantly
over the past 15 years,5,45,46 and ongoing research should focus on improving this outcome.45
Existing treatment options for gastrointestinal bleeding
Patients with acute severe GI bleeding usually present with hematemesis or melaena. Patients are often
haemodynamically unstable and in need of urgent resuscitation. Acute management of GI bleeding
includes blood product transfusion, medical or endoscopic therapy and surgery.
For patients with massive acute upper GI bleeding, the National Institute for Health and Care Excellence
(NICE) guidelines recommend transfusing patients with blood, platelets and clotting factors in line
with local protocols for managing massive bleeding.47 Patients with severe acute upper GI bleeding are
usually referred for endoscopy immediately after resuscitation. For the endoscopic treatment of non-
variceal upper GI bleeding, one of the following is recommended: a mechanical method (e.g. clips) with
or without adrenaline, thermal coagulation with adrenaline, or fibrin or thrombin with adrenaline.47
If endoscopy in such patients also reveals stigmata of recent haemorrhage, then proton pump inhibitors
are recommended.47 Interventional radiology is used in unstable patients who rebleed after endoscopic
treatment and these patients are urgently referred for surgery if interventional radiology is not immediately
available. Terlipressin is recommended for patients with suspected variceal bleeding at presentation.
For oesophageal varices, band ligation is often used, and transjugular intrahepatic portosystemic shunts may
be considered if the bleeding is not controlled by band ligation.47 For upper GI bleeding from gastric varices,
the NICE guidelines recommend endoscopic injection of N-butyl-2-cyanoacrylate and then, if that fails to
control the bleeding, transjugular intrahepatic portosystemic shunts.47
For patients with lower GI bleeding, the most common intervention is red blood cell (RBC) transfusion.48
Flexible sigmoidoscopy and colonoscopy can be used to provide endoscopic treatment, although this is
not commonly used in the UK.6 Radiological investigations are used in > 25% of cases.6 If extravasation
of contrast is shown on computed tomography angiography, formal, invasive angiography with the
option of mesenteric embolisation can be undertaken, although, in practice, embolisation is used in
< 1% of all cases.49
Tranexamic acid and gastrointestinal bleeding
In normal haemostasis, coagulation occurs rapidly at the site of a damaged blood vessel, forming a stable
fibrin blood clot. However, fibrinolytic enzymes in the blood can impair clot stability through the process
of clot breakdown, known as fibrinolysis.50 Fibrinolysis may play an important role in GI bleeding and
rebleeding because blood clots at the bleeding site may break down prematurely,51,52 which may worsen
the bleeding. Tranexamic acid (TXA) reduces bleeding by inhibiting fibrinolysis through the inhibition of
fibrin degradation by plasmin. It can, therefore, enhance the ability to form stable blood clots.
Tranexamic acid is commonly given to patients either before or during surgery to reduce bleeding and
the need for blood transfusion. It has been shown to decrease bleeding and the need for blood transfusion in
surgery and to reduce death due to bleeding in patients with traumatic and post-partum haemorrhage.53–55
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The knowledge that TXA reduces blood loss in surgery and reduces mortality in traumatic bleeding
raises the possibility that it might also be effective for GI bleeding.
Studies have shown that many patients with acute upper GI bleeding have elevated levels of fibrin
degradation products (a surrogate marker for fibrinolysis) and that this is associated with worse
outcomes.51,52 Fibrinolysis may also increase the risk of rebleeding. TXA reduces blood loss and the
need for transfusion when administered before and during surgery and increases survival in traumatic
bleeding, especially when given soon after injury. Early administration in patients with acute GI
bleeding could possibly reduce the duration and amount of bleeding at presentation and the risk of
rebleeding by stabilising blood clots at the bleeding site. This could reduce mortality and the need for
blood transfusion.
Existing research on tranexamic acid
Tranexamic acid is commonly given to surgical patients to reduce bleeding and the need for blood
transfusion. A systematic review of the effect of TXA in surgical patients showed that it reduces the
probability of blood transfusion by about one-third [risk ratio (RR) 0.62, 95% confidence interval (CI)
0.58 to 0.65], with no evidence of any increase in risk of thromboembolic events.53
Tranexamic acid decreases surgical bleeding and reduces death due to bleeding in patients with
traumatic and post-partum haemorrhage.54–57 The Clinical Randomisation of an Antifibrinolytic in
Significant Haemorrhage 2 (CRASH-2)54 trial showed that early administration of TXA reduces deaths
due to bleeding (RR 0.85, 95% CI 0.76 to 0.96) and all-cause mortality (RR 0.91, 95% CI 0.85 to 0.97)
in trauma patients, without increasing thromboembolic events. Among patients treated soon after
injury, the reduction in mortality with TXA is even greater.58 The Clinical Randomisation of an
Antifibrinolytic in Significant Head Injury 3 (CRASH-3)57 trial showed that early TXA treatment reduces
head injury deaths. Cost-effectiveness analysis reveals that the administration of TXA to bleeding
trauma patients is highly cost-effective.59 Based on these results, TXA was included in guidelines for
the pre-hospital care of trauma patients.
A systematic review and meta-analysis60 of TXA in patients with upper GI bleeding found a significant
reduction in all-cause mortality with TXA (RR 0.60, 95% CI 0.42 to 0.87; p = 0.007) and a non-significant
reduction in rebleeding (RR 0.72, 95% CI 0.50 to 1.03). However, the quality of the included trials was
poor and, therefore, this estimate is imprecise. Moreover, the included trials were too small to assess the
effect of TXA on thromboembolic events. Therefore, the effectiveness and safety of TXA in GI bleeding
remains uncertain.60
Rationale for trial
A meta-analysis60 of clinical trials on TXA in patients with upper GI bleeding found a significant
reduction in all-cause mortality with TXA (RR 0.60, 95% CI 0.42 to 0.87; p = 0.007). However, all but
one of the trials were conducted before the use of endoscopy and proton pump inhibitors and were
too small to assess the effect of TXA on thromboembolic events. The HALT-IT trial aims to provide
reliable evidence about the effects of TXA on death and thromboembolic events in acute GI bleeding.1
If TXA reduces mortality in patients with GI bleeding, this would be of considerable significance worldwide.
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Trial design
The HALT-IT trial was a large, international, pragmatic, randomised, double-blind, placebo-controlled
trial to quantify the effects of TXA (Cyklokapron® injection, Pfizer, Inc., New York, NY, USA) on
mortality and morbidity in adults with significant acute upper or lower GI bleeding.1 The trial protocol
was peer reviewed and published in BioMed Central’s Trials as an open access article in 2014.1
[See the trial protocol at the National Institute for Health Research (NIHR) Journals Library web page;
www.journalslibrary.nihr.ac.uk/programmes/hta/110104/#/documentation; accessed October 2021.]
The HALT-IT trial was the fourth international, multicentre, randomised, placebo-controlled trial in
significant haemorrhagic conditions conducted by the London School of Hygiene & Tropical Medicine
(LSHTM) Trial Co-ordinating Centre (TCC). CRASH-254 examined the effects of early administration
of a short course of TXA in trauma patients. The trial recruited 20,211 patients from 274 hospitals
in 40 countries. The World Maternal Antifibrinolytic (WOMAN)55 trial assessed the effects of early
administration of TXA on death, hysterectomy and other relevant outcomes in women with post-
partum haemorrhage. The WOMAN55 trial recruited 20,060 women from 193 hospitals in 21 countries.
CRASH-357 investigated the effects of TXA on death and disability in patients with traumatic brain
injury and recruited 12,737 patients from 175 hospitals in 29 countries.
The HALT-IT trial recruited patients from 164 hospitals in 15 countries. Suitable collaborating sites
and investigators were assessed on the number of potentially eligible patients and their ability to
conduct the trial. In advance of the trial starting at a site, all potential principal investigators had
to agree to follow good clinical practice guidelines and all relevant regulations in their country.
All relevant regulatory and ethics approvals were in place before the trial started at a site. See
Appendix 1 for a list of the trial collaborators by country.
Various treatments are used for GI bleeding and, as the trial was conducted worldwide, each participating
site was instructed to follow its own clinical guidelines for the treatment of patients with GI bleeding.
No clinically indicated treatment needed to be withheld for the trial. TXA or placebo was provided as a
treatment in addition to the usual management of GI haemorrhage.
Approvals
The Medical Research and Ethics Committee and Health Research Authority reviewed the HALT-IT
trial protocol and supporting documents and gave a favourable opinion on 13 March 2013 (Research
Ethics Committee reference 13/EE/0038). The Medicines and Healthcare products Regulatory Agency
(MHRA) granted authorisation for the HALT-IT trial on 12 February 2013 (reference 17072/0008/001-0001).
A favourable ethics opinion was received from the Observational/Interventions Research Ethics
Committee at LSHTM on 19 December 2012 (reference 6328). Protocol amendments and their
approval dates are listed in Amendments to the trial.
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All relevant approvals were also obtained from national and local research ethics committees and
national regulatory authorities, where applicable, in all participating non-UK countries.
Participants (inclusion and exclusion)
All adults with significant acute upper or lower GI bleeding were eligible for the trial. The diagnosis of
significant bleeding was clinical, but significant implies a risk of bleeding to death, and patients with
significant bleeding may include those with hypotension, tachycardia or signs of shock, as well as those
needing urgent transfusion, endoscopy or surgery. Patients were randomised once consent had been
obtained in accordance with the approved procedures.
The fundamental eligibility criterion was the responsible clinician’s ‘uncertainty’ as to whether or not
to use TXA in a particular patient with GI bleeding. The eligibility criteria were based on the uncertainty
principle, which is a well-established approach to trial eligibility.61 A patient could be enrolled if, and
only if, the responsible clinician was substantially uncertain as to which trial treatment would be the
most appropriate for that particular patient. A patient was not to be enrolled if the responsible clinician or
the patient (or his/her representative) were for any medical or non-medical reasons reasonably certain
that one of the two allocated treatments (TXA or placebo) would not be appropriate for this particular
individual (in comparison with either no treatment or some other treatment that could be offered).
In other words, patients in whom the responsible clinician considered there to be a clear indication
for TXA (e.g. traumatic haemorrhage) or contraindication to TXA (e.g. history of convulsions,
thromboembolic disease) were excluded.
The pragmatic design allowed us to find out how effective the treatment actually is in routine practice.
Clinicians, patients and their representatives were provided with information about the trial treatment
to assist them in their judgement. The TXA summary of product characteristics62 and an investigator’s
brochure were provided to investigators to ensure that they had adequate information when
considering the risk–benefit ratio and the appropriateness of the trial for each patient.
Consent
Significant acute GI bleeding is an emergency, and the priority is to provide appropriate emergency
care. Eligible patients have a life-threatening condition. Their physical, mental and emotional state may
be affected by their blood loss. This may impair their decision-making and affect their ability to give
prior informed consent to participate in the trial. Because randomisation and administration of the
trial treatment should be undertaken as early as possible once significant GI bleeding is suspected,
the consent process in this situation required careful consideration, bearing in mind the applicable
regulatory requirements, adherence to the International Council for Harmonisation – Good Clinical
Practice63 and the requirements in the Declaration of Helsinki.64 As acknowledged in the Declaration of
Helsinki, patients who are incapable of giving consent are an exception to the general rule of informed
consent in clinical trials.64
In the HALT-IT trial, bearing in mind the clinical situation and the patient’s level of distress, the patient
and, if present, the patient’s relative were provided with brief information about the trial (see the brief
information sheet in Appendix 2). If the patient was fully competent, written consent was sought. If the
patient’s capacity was impaired and a personal or professional representative was available, consent
was sought from the patient’s representative. If the patient or their representative objected to the
inclusion of the patient in the trial, their views were respected and the patient was not enrolled.
METHODS
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If neither was able to provide informed consent, the need for consent was waived. This process
involved the investigator and one independent person who was not participating in the trial enrolling
the patient. They were required to confirm that the patient had significant GI bleeding and was unable
to give consent because of their condition, that it was not feasible to contact a representative for the
patient to obtain consent, and that they were not aware of any objections to the patient participating
in the trial. The patient, or their representative, was then informed about the trial and asked for consent
for ongoing data collection as soon as possible afterwards. If the patient or their representative declined
consent, participation stopped.
The approach that allowed the patient to have the most input into the decision-making process
without endangering their life was utilised. If the person giving consent was unable to read or write,
the information sheet was read to them and they then marked the consent form with either a cross
or a thumbprint. In this event, a witness not associated with the trial was required to provide a full
signature confirming the mark.
All requirements of local and national ethics committees were adhered to (see Appendix 3 for an
overview of the consent procedure).
Randomisation and blinding
Patient eligibility was determined from routinely collected clinical information and recorded on the
trial entry form (see Appendix 4). No trial-specific tests were required. Sites were advised to randomise
eligible patients as soon as possible. Following confirmation of eligibility, patients were randomly
allocated to receive TXA or matching placebo (sodium chloride 0.9%) by intravenous injection in the
case of the loading dose and by intravenous infusion in the case of the maintenance dose. Block
randomisation was used but randomisation was not stratified. Randomisation codes were generated
and secured by an independent statistician from Sealed Envelope Ltd (London, UK). The codes were then
given to Sharp Clinical Services, UK (Crickhowell, UK), a good manufacturing practice (GMP)-certified
clinical trial service provider, to make the treatment packs in accordance with the randomisation list.
After baseline information was collected on the entry form, patients were randomised by taking the
next lowest consecutively numbered pack from a box of eight treatment packs. At the point when all of
the treatment ampoules were confirmed as being intact, the patient was considered to be randomised
to the trial. The trial treatment was then started immediately. Once a patient was randomised, the
entry form data were sent to the TCC as soon as possible. This was carried out by trial team members
entering the data into a secure online database.
Both participants and study staff (site investigators and TCC staff) were masked to treatment
allocation. An emergency unblinding service was available for use in the rare situations when the
clinician believed that clinical management depended on the knowledge of whether the patient had
received TXA or placebo.
Pfizer Manufacturing (Sandwich, UK) (marketing authorisation number PL 00057/0952) manufactured
the TXA (cyklokapron injection) and Torbay and South Devon NHS Foundation Trust [manufacturing
authorisation number (investigational medicinal product) 13079] manufactured the sodium chloride
0.9% placebo. The ampoules and packaging were identical in appearance.
Sharp Clinical Services, UK (Crickhowell, UK) [manufacturing authorisation number (investigational
medicinal product) 10284], was responsible for masking, manufacturing the study drug treatment
packs, which contained either the active drug TXA or placebo and the first-stage qualified person
(QP) release. This involved removing the original manufacturer’s label and replacing it with the clinical
trial label and treatment pack number. Apart from the randomisation number, the pack label text was
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identical for TXA and placebo. Sharp Clinical Services, UK, was also responsible for maintaining the
product specification file until final database lock and unblinding of the trial data.
The coding of the blinded ampoules was checked by testing random samples of final QP-released
drug packs from each batch with high-performance liquid chromatography to determine the contents.
The tested samples were unblinded to assure accuracy of blinding.
Trial intervention
Eligible patients were randomised to TXA or placebo as soon as possible and the treatment was
started immediately. Patients received a loading dose of 1 g of TXA or placebo (sodium chloride 0.9%),
which was added to a 100-ml infusion bag of 0.9% sodium chloride and infused by slow intravenous
injection over 10 minutes. This was followed by a maintenance dose of 3 g of TXA or placebo added to
1 litre of any isotonic intravenous solution and infused at 125 mg/hour for 24 hours. The maintenance
dose was started as soon as the loading dose was completed. Where fluid restriction was required,
the volume used to administer the maintenance dose could be reduced to 500 ml.
Every patient was assigned a uniquely numbered treatment pack, each of which contained eight
ampoules of TXA 500 mg or placebo, one 100-ml bag of 0.9% sodium chloride (to use with the loading
dose), two sterile 10-ml syringes and needles, stickers with the trial details and randomisation number
(for attaching to infusion bags, forms and the medical records), and instructions. The lowest-numbered
treatment pack was taken from a box of eight packs. We separately provided information for patients
and representatives, consent forms and data collection forms. The stickers, instructions, leaflets and
forms were in local languages.
The TCC was responsible for ensuring that all relevant approvals were available at the TCC before release
of the trial treatment to a site. A separate manual of operating procedures detailed the drug accountability
system. The investigator’s brochure and investigational medicinal product dossier provided detail about
the labelling of the trial treatment and other processes for ensuring adherence to GMP.
Dose selection
Tranexamic acid has been used to reduce bleeding in elective surgery for many years. In randomised
trials in cardiac surgery, TXA dose regimens vary widely. Loading doses range from 2.5 to 100 mg/kg
and maintenance doses range from 0.25 to 4 mg/kg/hour, which are given over periods of 1–12 hours.65
A loading dose of 10 mg/kg of TXA followed by an infusion of 1 mg/kg/hour has been shown to
produce plasma concentrations sufficient to inhibit fibrinolysis in vitro.66 In emergency situations,
the administration of a fixed dose is more practicable, given that weighing patients is difficult. In the
CRASH-2 trial, a fixed dose of a 1-g loading dose of TXA followed by a 1-g maintenance dose over
8 hours was found to reduce mortality in bleeding trauma patients, with no evidence of significant
adverse effects.54,58 In the HALT-IT trial, a fixed dosage of a 1-g loading dose of TXA followed by 3 g
infused over 24 hours was selected. This dosage is within the range that has been shown to inhibit
fibrinolysis.66 It was efficacious for larger patients (> 100 kg) but was also safe for smaller patients
(< 50 kg), given that the estimated dose per kilogram that the patients in the latter group would receive
has been applied in other trials without significant adverse effects.65,66 The loading dose (1 g) is the same
as was used in the CRASH-254 and CRASH-357 trials. A maintenance dose is provided but over a longer
duration (24 hours) than in the CRASH-254 and CRASH-357 trials to cover the period when the patient is
at greatest risk of rebleeding.
METHODS
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Sites
We recruited patients with significant acute upper or lower GI bleeding from 164 hospitals in
15 countries. We enrolled the first patient on 4 July 2013 and the last patient on 21 June 2019.
We stopped recruiting when the planned sample size was reached. A total of 12,009 patients were
enrolled worldwide. See Appendix 5 for the total number of randomised patients by geographical region.
Data collection
Data were collected at each site by local investigators and transmitted to the TCC. Only data outlined
on the entry, outcome and adverse event forms were collected for this trial.
To allow for variation in available technology for data transfer, a variety of methods were used. Data
were collected by the investigator on paper case report forms and transmitted to the TCC by fax or
e-mail, or by entering the data directly into the trial database. The data were used in accordance with
local laws and ethics committee approval.
Baseline data
The trial entry form (see Appendix 4) was used to collect the following baseline characteristics:
age, biological sex, time from onset of GI bleeding symptoms to randomisation, suspected location
of bleeding, clinical symptoms (e.g. haematemesis and melaena), suspected variceal bleeding, systolic
blood pressure (SBP), heart rate, signs of shock, suspected active bleeding, major comorbidities,
anticoagulation therapy and type of admission. Relevant data were recorded on the entry form to
assess the patient’s eligibility before randomisation and the form was completed if the patient
was randomised.
Outcome data
The trial protocol required the outcome form (see Appendix 6) to be completed at death, discharge
from the randomising hospital or 28 days after randomisation, whichever occurred first. These
data were collected from the patients’ routine medical records because no special tests were required.
Any adverse events that became known to the investigator were reported up to 28 days after
randomisation. Once patients were randomised, outcome data were collected even if the treatment
was interrupted or was not actually given. Specific patient-orientated outcomes were assessed.
Initially, the collection of patient-identifiable information, including a patient’s name, date of birth,
NHS number and postcode, was planned to allow trial staff based at LSHTM to follow up the patients’
status at 12 months after randomisation. Follow-up was planned by linking this personal information
to Hospital Episode Statistics through the Trusted Data Linkage Service of the NHS Information
Centre for England and to the Patient Episode Database for Wales through the Secure Anonymised
Information Linkage Databank.
In July 2018, the outcome form was modified to allow the collection of the date or dates on which the
patients experienced rebleeding.
Monitoring
The trial was assessed as low risk, because TXA is widely used; the trial collected adverse event data,
which were then reviewed routinely by the independent Data Monitoring Committee (DMC), and all
treatment apart from the study drug was given as per usual practice. Therefore, central trial monitoring
and central statistical monitoring were used in conjunction with investigators’ training and meetings,
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and extensive written guidance, to make sure that the trial was carried out properly. Trial investigators
and their institutions provided direct access to the source data for trial-related monitoring, audits and
regulatory inspections. Monitoring was carried out in accordance with the sponsor’s standard operating
procedure and the trial protocol. Formal inspections were carried out by the relevant regulatory agencies
including the UK MHRA, Irish Health Products Regulatory Authority and Nigeria’s National Agency
for Food and Drug Administration and Control. The adherence to allocation sequence was monitored
throughout the trial and any out-of-sequence pack use was automatically flagged in the trial database
and the investigators were retrained.
The progress of the HALT-IT trial, including recruitment, data quality, outcomes and safety data, was
reviewed by an independent DMC. Four interim analyses were conducted by the DMC in total.
Outcome measures
Primary outcome
The primary outcome was death due to bleeding within 5 days of randomisation. The primary end point
was originally death due to bleeding within 28 days of randomisation, but the protocol was changed in
March 2019. Cause of death was assigned by local principal investigators, who provided a narrative of the
events leading to death. These were reviewed by the chief investigator (blind to treatment allocation) and
queried if more information was needed to confirm whether death was due to bleeding or another cause.
Secondary outcome
Secondary outcomes were death due to bleeding within 24 hours and within 28 days of randomisation,
all-cause and cause-specific mortality at 28 days, rebleeding within 24 hours, within 5 days and within
28 days of randomisation, surgery or radiological intervention, blood product transfusion, thromboembolic
events (i.e. deep-vein thrombosis, pulmonary embolism, stroke and myocardial infarction), seizures, other
complications (including other significant cardiac event, sepsis, pneumonia, respiratory failure, renal failure
and liver failure), days in an intensive care unit (ICU), and functional status.
Death due to bleeding within 28 days was changed to a secondary outcome in March 2019. The diagnosis
of rebleeding was made by the clinician based on established criteria. A diagnosis of thromboembolic
events was made using strict definitions and diagnostic criteria, including a clinical assessment, diagnostic
imaging, biomarker tests and post-mortem examination. Seizures were diagnosed by clinical assessment.
Functional status was measured with the Katz Index of Independence in Activities of Daily Living either at
hospital discharge or in hospital at 28 days.
Adverse events
Tranexamic acid is not a new drug and has a well-documented safety profile. Although the Summary
of Product Characteristics62 suggests that rare cases of thromboembolic events and seizures might be
associated with TXA administration, there is no evidence that the TXA treatment regimen used in this
trial is associated with an increased risk of thromboembolic events or seizures.
Nevertheless, data on thromboembolic events (e.g. deep-vein thrombosis, pulmonary embolism,
myocardial infarction and stroke), seizures, other significant cardiac event, and respiratory, liver and
renal failure were collected as secondary outcomes up to day 28 after randomisation and were
presented to the independent DMC for unblinded review.
METHODS
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Amendments to the trial
Various amendments were made to the HALT-IT trial throughout the time that it was being conducted.
The main amendments and the rationale for them are summarised below.
Substantial amendment to the protocol from version 1.0 to version 1.1 (UK), August 2014
The UK protocol was amended to clarify that clinicians in participating hospitals would at all times retain
the freedom to act in the patient’s best interest, and that each participating site should follow its own
clinical practice for the treatment of GI bleeding. Centres in which TXA is in routine use (including those
where it is either specifically mandated or recommended for GI bleeding in a massive haemorrhage
treatment protocol) were excluded from taking part in the trial. This amendment included monitoring
the use of open-label TXA for the treatment of GI bleeding at collaborating sites and the procedure to
be followed at sites where this is common.
Rationale
These changes were made in line with the recommendations of the Research Ethics Committee. The
Data Access Advisory Group, Health and Social Care Information Centre also requested an amendment
to the information sheet and consent form to allow data on patient status in England and Wales to be
shared with us at 1 year.
This amendment was approved by the Multicentre Research Ethics Committee (MREC) on 12 August 2014
and by the MHRA on 21 August 2014.
Non-substantial amendment to the protocol from UK version 1.1 to version 1.2 and
international protocol version 1.0 to version 1.1, October 2016
The protocol was updated to version 1.2 to extend the planned date of last patient enrolment by
1 year, from 30 November 2016 to 30 November 2017.
Rationale
A delay in the issue of the funding contract had led to recruitment starting late. The recruitment
extension was necessary to ensure that the target number of patients were recruited.
Substantial amendment to increase the number of patients from the UK and European
Economic Area, February 2017
A substantial amendment was submitted to increase the UK sample size from 4000 to 5000 patients, and
to increase the European Economic Area sample size from 5000 to 6000 patients. The total international
sample size remained as 8000 patients. The protocol was not updated as a result of this amendment.
Rationale
When the original trial application was submitted, there were no reliable data on which to base
recruitment in the UK. We, therefore, originally planned for a more conservative number. However,
recruitment in the UK was much higher than anticipated.
This amendment was approved by the MREC on 27 February 2017.
Substantial amendment to the protocol from version 1.2 (UK) and version 1.1 (international)
to version 2.0, November 2017
This amendment increased the sample size from 8000 to 12,000 patients and added death from
haemorrhage as the main secondary outcome. The recruitment period was also extended by 18 months
from 30 November 2017 to 31 May 2019.
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Rationale
Accumulating evidence of the effect of TXA on traumatic bleeding (CRASH-2 trial54) and post-partum
haemorrhage (the WOMAN trial55) showed that TXA reduces deaths from haemorrhage with no
apparent effect on any other cause of death. The reductions in bleeding deaths in trauma and obstetric
patients provided good reason to anticipate that TXA may reduce bleeding deaths (but not other
causes of death) in patients with GI haemorrhage. The primary outcome in the HALT-IT trial was all-
cause mortality within 28 days of randomisation. This was based on the assumption that most deaths
in the trial would be from bleeding. However, the accumulated (blinded) data showed that a substantial
proportion of deaths are not bleeding related (e.g. cancer, pneumonia and liver failure). Given that the
effect of TXA was likely to be on death from haemorrhage, with the original sample size of 8000 patients
there was a risk that the trial might fail to detect a clinically relevant treatment benefit, leaving the
therapeutic question unresolved. The sample size was, therefore, increased from 8000 to 12,000 patients
and death from haemorrhage was added as the main secondary outcome. The recruitment period was also
extended by 18 months. The increase in the sample size meant that the trial should have enough power to
detect a reduction in death from haemorrhage, and there would be a smaller chance of missing a clinically
important reduction in all-cause mortality. This amendment was given a favourable opinion by the MREC
on 23 October 2017 and was approved by the MHRA on 14 November 2017.
Substantial amendment to the protocol from version 2.0 to version 2.1 (UK), May 2018
An amendment to the UK protocol was made to provide clarification on the definition of ‘significant
bleeding’, stating that ‘the diagnosis of significant bleeding is clinical but significant implies a risk of
bleeding to death and may include patients with hypotension, tachycardia, signs of shock, or those
needing urgent transfusion, endoscopy or surgery’.
Rationale
This amendment was submitted following the recommendation of MHRA. This amendment was given a
favourable opinion by the MREC on 1 May 2018 and was approved by the MHRA on 25 May 2018.
Substantial amendment to the outcome form from version 1.0 to version 2.0,
September 2018
This amendment was submitted to retrospectively collect the date when patients experienced rebleeding.
The outcome form was modified to allow the collection of the date when any rebleeding took place.
Rebleeding was a secondary outcome of the HALT-IT trial, and if patients experienced rebleeds this
was captured in the outcome form as a complication. The outcome form was completed 28 days after
randomisation, at discharge from the randomising hospital or at death, whichever occurred first.
Rationale
In addition to reducing the duration and amount of bleeding, early administration of TXA could reduce
the risk of rebleeding. However, a patient may experience a rebleed long after having received the trial
treatment, and this would be recorded if it occurred up to 28 days post randomisation. In some cases,
even if a patient received TXA, this may have little or no biological effect if the rebleed occurred
outside the TXA therapeutic window. The amendment was given a favourable opinion by the MREC
on 24 August 2018 and was approved by the MHRA on 9 September 2018.
Substantial amendment to the protocol from version 2.1 (UK) and version 2.0 (international)
to version 3.0, November 2018
The decision to refine the primary outcome was made by the Trial Steering Committee in November 2018.
The primary outcome was changed from death from all causes within 28 days of randomisation to
death from haemorrhage within 5 days of randomisation. Death from haemorrhage within 28 days of
randomisation, all-cause and cause-specific mortality within 28 days of randomisation and need for
endoscopy were added as secondary outcomes. The recruitment period was extended by 4 months from
31 May 2019 to 30 September 2019.
METHODS
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Rationale
Tranexamic acid is an antifibrinolytic drug that helps to stop bleeding by inhibiting the breakdown of
fibrin blood clots. Combined data from large randomised controlled trials (RCTs) using TXA in acute
severe haemorrhage have shown that TXA reduces deaths from haemorrhage with no apparent effect
on other causes of death. The original primary outcome in the HALT-IT trial (all-cause mortality
within 28 days) was based on the assumption that most deaths in the trial would be due to bleeding.
However, an analysis of blinded data shows that over half (55%) of patients died from non-bleeding
causes, such as cancer, pneumonia and liver failure. Because all-cause mortality is a composite of
different causes of death, the treatment effect on all-cause mortality is a weighted average of the
cause-specific effects. For example, assuming that 45% of deaths are due to bleeding and that TXA
reduces deaths by 25% but has no effect on other causes of death, the treatment effect on all-cause
mortality would be:
RR = (0:45 × 0:75) + (0:55 × 1:00) = 0:89: (1)
The inclusion of non-bleeding causes of death, which are unlikely to be affected by TXA, would dilute
the treatment effect towards the null, reducing the power to detect an effect if one exists. Although the
original sample size of 8000 patients was increased to 12,000, if non-bleeding deaths are unaffected
by TXA, even with 12,000 patients, the trial would have low power to detect an effect on all-cause
mortality. For example, a trial with a 10% event rate would have just 54% power to detect an 11%
reduction in all-cause mortality. By contrast, a trial with a 4% event rate would have 85% power to
detect a 25% reduction in death from haemorrhage. By changing the primary outcome, the power
of the trial was substantially increased. In addition, because the relative contributions of different
causes of death vary within and between patient populations, all-cause mortality is not a generalisable
outcome measure. Finally, around 10% of patients with acute GI bleeding experience rebleeding,
which affects > 50% of those with variceal bleeding and is associated with increased mortality. These
rebleeding episodes can occur several days or weeks after the index bleed. Patients receive TXA
(or placebo) for their index bleed but not for rebleeding episodes. TXA has a half-life of around 3 hours
and, therefore, is unlikely to affect the risk of late death due to bleeding that occurs after it has been
excreted. Therefore, we chose to restrict the primary outcome to early deaths from haemorrhage,
defined as those occurring within 5 days of randomisation. In summary, changing the primary outcome
to death from haemorrhage within 5 days of randomisation should have provided adequate power to
detect a plausible reduction in death due to bleeding.
This amendment received a favourable opinion from the MREC on 10 April 2019 and MHRA approval
on 25 April 2019.
Sample size
The original sample size estimate assumed a control group all-cause mortality risk of 10%. It was,
therefore, originally estimated that a trial with 8000 patients would have > 90% power (two-sided
alpha of 5%) to detect a 25% reduction (RR 0.75) in all-cause mortality. The sample size calculation was
initially based on all-cause mortality as the primary outcome because we expected that most deaths
would be due to bleeding.1 However, while the trial was under way, we observed that over half of all
deaths were due to non-bleeding causes. Accumulating evidence from other large trials of TXA found
no apparent effect on non-bleeding deaths.67 The sample size was, therefore, increased to 12,000 patients
to provide adequate power to detect a plausible reduction in death from haemorrhage and all-cause
mortality. The trial was then estimated to have > 80% power to detect a 15% (RR 0.85) reduction in
all-cause mortality. In 2019, the primary outcome was changed to death due to bleeding within 5 days
of randomisation. Based on the amended primary outcome, and assuming a risk of death due to
bleeding of 4%, a study with 12,000 patients would have about 85% power (two-sided alpha = 5%)
to detect a clinically important 25% relative reduction in death due to bleeding from 4% to 3%.
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Statistical methods and analysis plan
The statistical analysis plan was published before unblinding.2 The plan gave our reasons for amending
the primary outcome measure and for increasing the sample size. The main analyses compared those
patients allocated to TXA with those allocated to placebo on a modified intention-to-treat basis,
excluding patients who received neither dose of the allocated treatment. Effect estimates (RRs) were
calculated with a measure of precision (95% CIs). The safety of participants was overseen by an
independent DMC, which reviewed four unblinded interim analyses.
Subgroup analysis
Four subgroup analyses were planned to examine the effects of TXA on the primary outcome stratified
by the following baseline characteristics: time to treatment (≤ 3 vs. > 3 hours), site of bleeding (upper
vs. lower GI), cause of bleeding (suspected variceal bleeding and/or comorbid liver disease vs. other or
unknown causes) and clinical Rockall score. We fitted an interaction term between treatment group
and each of the subgroup factors in a Poisson regression model. We used a test for interaction to
explore whether or not the treatment effect (if any) varied across the subgroups. Time to treatment
was analysed as both a categorical and a continuous variable. Post hoc subgroup analyses were conducted
to examine the effects of TXA on the primary outcome stratified by World Bank classification of country
income level (high vs. low or middle income), anticoagulant use and SBP.
Economic evaluation methods
An economic analysis was conducted to evaluate the cost-effectiveness of the current standard of
care for people with AGIB with and without the administration of TXA. The evaluated TXA regimen
mirrored that used in the HALT-IT trial. The analysis followed the NICE technology appraisal guidelines
for conducting economic evaluations.68 The evaluation used a decision model to combine the clinical
results from the HALT-IT trial with evidence from other sources to estimate costs and outcomes over
a lifetime horizon for the two treatment options. The analysis adopts a UK NHS cost perspective
and expresses health outcomes in terms of life-years (LYs) and quality-adjusted life-years (QALYs).
Full details of the methods and results are provided in Chapter 5.
Patient and public involvement
Patient and public involvement (PPI) that was previously conducted by the TCC team was used to
inform the HALT-IT trial procedures and to achieve the following objectives:
l to gain lay perspectives on PPI involvement in the design and management of emergency care
clinical trials
l to identify an appropriate consent procedure for entering critically ill trauma patients into
emergency clinical trials that could be used for the HALT-IT trial
l to ensure that patient-facing documents for the trial were appropriate and clear
l to provide a lay perspective on the management of the trial and interpretation of the results.
We included PPI groups’ input into different stages of the trial; this included people who suffered
severe haemorrhage. Formative research and research with a PPI group had previously been
carried out to guide the PPI activities for our programme of emergency care research. The outcome
of much of this PPI engagement was used to inform the HALT-IT trial procedures. This is
summarised below.
METHODS
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Formative research method
A qualitative study was conducted to elicit views on how best to involve patients and the public in the
design, conduct and reporting of clinical trials involving people in emergency situations, gathering
perspectives on which areas of the research programme they believed that public contribution would
be most appropriate. Approaches to designing a consent process to enter patients into emergency
clinical trials were also explored.
Specifically for the HALT-IT trial, two focus group discussions were carried out involving a group of
older men belonging to a social club and a group of older women who were involved in a continuing
education project and crafts-based activities.
The sessions included a PowerPoint® (Microsoft Corporation, Redmond, WA, USA) presentation detailing
why clinical trials are conducted in emergency medicine, how they are conducted and the key principles,
including issues of consent, randomisation and the use of placebos. This was followed by three exercises
using group work and discussion techniques.
Two key areas of inquiry emerged from these discussions: public involvement in the design and
management of clinical trials and decisions about entering patients into clinical trials in an emergency.
Formative research outcome: involvement in clinical trial design and management
Participants were highly supportive of clinical medical research, seeing it as essential for the progress of
medical science. They also had a sense that the public should be consulted in principle. However, they
struggled to identify how they might usefully contribute to the design and management of clinical trials
in practice, seeing this as the province of highly skilled and qualified experts. Although there were
individuals who could envisage a role for themselves with appropriate information and preparation, it
was important to acknowledge that others felt that they had neither the inclination nor the aptitude to
become involved, trusting the expertise and competence of clinical researchers. Participants did have
strong opinions in one area, namely that decision-making about the outcomes of clinical research should
not be confined to treatment efficacy or safety but must take account of quality-of-life issues, which
they considered patients and the public to be well placed to comment on.
Formative research outcome: consent process for involving patients in clinical trials in
an emergency
Initially, a minority opposed entering patients into trials without their consent, but these views tended
be modified as participants considered the comments of others about the incapacitation of patients,
the time-critical nature of emergency medicine and the necessity of clinical trials for medical progress.
Overall, among both groups there was a very high regard for the medical profession and a strong faith
in the skills and competence of medics, as well as a belief that clinicians would always act in the best
interest of the patient. This was reflected in a sense that clinicians should be allowed to exercise their
clinical judgement without undue burden to seek consent from next of kin when patients could not
consent for themselves. However, moderating this perspective for some was a belief in the principle that,
where practicable, next of kin should be consulted; others argued that this might place a heavy burden
of responsibility on families and that the clinician’s greater expertise may in fact render better decisions.
Interestingly, when the participants were asked what they would want for themselves, all the
participants expressed a desire for the clinician (or their own family) to enter them into the trial.
Patient and public involvement for the HALT-IT trial
Drafts of the brief information sheet, full information sheet and consent form were reviewed by
PPI representatives.
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A PPI representative who had experience of severe gastrointestinal haemorrhage provided a lay
perspective on the management of the trial as part of the Trial Steering Committee. They also provided
a lay perspective on the trial results and dissemination as part of the Writing Committee for the trial.
Outcome of patient and public involvement
Patient and public involvement contributed to the success of the trial. The consent process that was
developed with PPI groups was used in all countries that took part in the trial, and was accepted by all
ethics committees and regulatory agencies, with only local modifications needed.
METHODS
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Chapter 3 Baseline results
The first patient was enrolled on 4 July 2013 and the last patient was enrolled on 21 June 2019.Recruitment ended when the planned sample size of 12,000 patients had been reached. When the
decision to refine the primary outcome was made in November 2018, we had recruited 10,190 patients.
This decision was made blind to the accumulating trial data.
A total of 12,009 patients were enrolled and randomly assigned to received either TXA (n = 5994,
49.9%) or matching placebo (n = 6015, 50.1%), of whom 11,952 (99.5%) received the first dose of the
allocated treatment (Figure 1). A total of 29 patients (11 in the TXA group and 18 in the placebo group)
withdrew consent after randomisation, but, of those, 12 (five in the TXA group and seven in the
placebo group) agreed to provide outcome data or had outcome data collected as part of adverse
event reporting. We obtained primary outcome data for all but three patients in the TXA group. There
were 14 protocol violations (seven in the TXA group and seven in the placebo group). Eleven patients
did not meet the inclusion criteria [10 received TXA prior to randomisation (six in the TXA group and
four in the placebo group) and one patient in the placebo group was aged < 16 years] and there were
three consent protocol violations (one in the TXA group and two in the placebo group). A total of
28 patients were unmasked to treatment [17 because the hospital team wanted to administer TXA,
six because of adverse events, three because of clinical concerns and two as part of post-mortem
investigations (13 in the TXA group and 15 in the placebo group)]. Fifty-two patients received neither
dose of the allocated trial treatment (29 patients in the TXA group and 23 patients in the placebo
group). A total of 223 patients received antifibrinolytic drugs as part of their clinical care, outside
the trial protocol (105 patients in the TXA group and 118 patients in the placebo group). Baseline
characteristics were similar in both groups (Table 1).
Patients randomly assigned
(n = 12,009)
Assigned to TXA and
baseline data collected
(n = 5994)
Assigned to placebo and baseline
data collected
(n = 6015)
Received loading dose, n = 5964
Received maintenance dose, n = 5483
Received neither dose, n = 29
Received loading dose, n = 5988
Received maintenance dose, n = 5510
Received neither dose, n = 23
Consent withdrawn and outcome
data unavailable, n = 6
Lost to follow-up, n = 3
Consent withdrawn but outcome
data provided, n = 5
With outcome data, n = 5985
Received allocated treatment and
included in the primary analysis,
n = 5956
With outcome data, n = 6004
Received allocated treatment and
included in the primary analysis,
n = 5981
Consent withdrawn and outcome
data unavailable, n = 11
Consent withdrawn but outcome
data provided, n = 7
FIGURE 1 Trial profile.
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TABLE 1 Baseline characteristics of participants prior to randomisation
Baseline characteristic
Treatment group, n (%)
TXA (N= 5994) Placebo (N= 6015)
Age at randomisation (years)
Mean (SD) 58.1 (17.0) 58.1 (17.0)
< 40 791 (13) 779 (13)
40–59 2356 (39) 2333 (39)
60–79 2078 (35) 2130 (35)
≥ 80 769 (13) 773 (13)
Sex
Female 2142 (36) 2124 (35)
Male 3852 (64) 3891 (65)
Time from onset to randomisation (hours)
Mean (SD) 21.4 (36.4) 22.5 (37.8)
≤ 3 960 (16) 975 (16)
> 3 to ≤ 8 1607 (27) 1551 (26)
> 8 3427 (57) 3488 (58)
Missing 0 1 (< 1)
Suspected location of bleeding
Lower GI tract 674 (11) 654 (11)
Upper GI tract 5320 (89) 5361 (89)
Haematemesis
Yes 4285 (72) 4240 (71)
No 1709 (29) 1775 (30)
Melaena or fresh blood per rectum
Yes 4573 (76) 4626 (77)
No 1421 (24) 1389 (23)
Suspected variceal bleeding
Yes 2694 (45) 2739 (46)
No 3300 (55) 3276 (54)
Suspected active bleeding
Yes 5247 (88) 5226 (87)
No 747 (12) 789 (13)
SBP (mmHg)
≥ 90 5222 (87) 5216 (87)
76–89 577 (10) 577 (10)
≤ 75 181 (3) 201 (3)
Missing 14 (< 1) 21 (< 1)
BASELINE RESULTS
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TABLE 1 Baseline characteristics of participants prior to randomisation (continued )
Baseline characteristic
Treatment group, n (%)
TXA (N= 5994) Placebo (N= 6015)
Heart rate (beats per minute)
< 77 812 (14) 756 (13)
77–91 1546 (26) 1644 (27)
92–107 1760 (29) 1720 (29)
> 107 1864 (31) 1885 (31)
Missing 12 (< 1) 10 (< 1)
Signs of shock
Yes 2574 (43) 2648 (44)
No 3420 (57) 3367 (56)
Rockall score
1–2 1419 (24) 1395 (23)
3–4 2306 (38) 2332 (39)
5–7 2269 (38) 2288 (38)
Taking anticoagulants
Yes 528 (9) 500 (8)
No 5422 (90) 5466 (91)
Unknown 44 (1) 49 (1)
Emergency admission
Yes 5673 (95) 5687 (94)
No 321 (5) 328 (6)
Major comorbidities
Cardiovascular 1108 (18) 1132 (19)
Respiratory 337 (6) 324 (5)
Liver 2432 (41) 2532 (42)
Renal 325 (5) 310 (5)
Malignancy 417 (7) 382 (6)
Other 999 (17) 968 (16)
Any comorbidity 4308 (72) 4329 (72)
SD, standard deviation.
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Chapter 4 Outcome and results
Outcome data were available for 11,989 randomised patients (5985 patients allocated to the TXAgroup and 6004 patients allocated to the placebo group). A total of 11,952 (99.5%) patients received
the loading dose of the allocated treatment and 10,993 (91.5%) received the 24-hour maintenance dose.
Primary outcome
Figure 2 shows the number of deaths and cause of death by days since randomisation. There were
1121 deaths in total. The median time to death was 55 hours after randomisation (interquartile range
18.2–161.8 hours).
Death due to bleeding within 5 days of randomisation (Table 2) occurred in 222 patients (3.7%) in the TXA
group and in 226 patients (3.8%) in the placebo group (RR 0.99, 95% CI 0.82 to 1.18). Similar results were
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FIGURE 2 Mortality by days from randomisation.
TABLE 2 Effect of TXA on death due to bleeding and rebleeding
Treatment group, n (%)
RR (95% CI)TXA (N= 5956) Placebo (N= 5981)
Death due to bleeding within 24 hours 124 (2.1) 120 (2.0) 1.04 (0.81 to 1.33)
Death due to bleeding within 5 days 222 (3.7) 226 (3.8) 0.99 (0.82 to 1.18)
Death due to bleeding within 28 days 253 (4.2) 262 (4.4) 0.97 (0.82 to 1.15)
Rebleeding within 24 hoursa 41 (0.7) 41 (0.7) 1.00 (0.65 to 1.55)
Rebleeding within 5 daysa 287 (4.8) 315 (5.3) 0.91 (0.78 to 1.07)
Rebleeding within 28 daysa 410 (6.8) 448 (7.5) 0.92 (0.81 to 1.05)
a Excludes 13 patients missing data on rebleed status or rebleed date.
Death or rebleeding in hospital during follow-up.
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analysis (RR 0.94, 95% CI 0.71 to 1.23).When the 223 patients who received open-label antifibrinolytics
were removed from the analysis, the results were similar (RR 0.97, 95% CI 0.81 to 1.17) (Table 3).
Subgroup analysis
We examined the effect of TXA on death due to bleeding within 5 days of randomisation in prespecified
subgroup analyses stratified by time to treatment (heterogeneity p = 0.53), location of bleeding (p = 0.34),
cause of bleeding (p = 0.94) and clinical Rockall score (p = 0.32), but recorded no evidence of heterogeneity
for these factors (Figure 3). When time since bleeding onset was modelled as a continuous variable,
there was no evidence of an interaction (heterogeneity p = 0.53).
We examined the effect of TXA on death due to bleeding within 5 days of randomisation, stratified by
the World Bank’s classification of country income level (high vs. low or middle income), anticoagulant
use and SBP. These exploratory analyses were not prespecified. The RRs did not appear to vary by
country income, anticoagulant use or SBP.
TABLE 3 Patients’ risk of death within 5 days of randomisation to treatment with TXA or placebo, excluding patients
who received off-label antifibrinolytics, vasopressin or proton pump inhibitors
Treatment group, n/N (%)
RR (95% CI)TXA Placebo
No antifibrinolytics 214/5854 (3.66) 220/5867 (3.75) 0.97 (0.81 to 1.17)
No vasopressin 76/3608 (2.11) 77/3554 (2.17) 0.97 (0.71 to 1.33)
No proton pump inhibitor 23/647 (3.55) 20/588 (3.4) 1.05 (0.58 to 1.88)
TXA
(N = 5956), n (%)
Placebo



























































FIGURE 3 Effect of TXA on death due to bleeding within 5 days. Analysis stratified by time since bleeding onset,
suspected bleed location, suspected variceal bleeding or comorbid liver disease, and Rockall score.
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Secondary outcome
Death due to bleeding within 24 hours of randomisation occurred in 124 (2.1%) patients in the TXA group
and 120 (2.0%) patients in the placebo group. Death due to bleeding within 28 days of randomisation
occurred in 253 (4.2%) patients in the TXA group and 262 (4.4%) patients in the placebo group (RR 1.04,
95% CI 0.81 to 1.33) (Figure 4). Death due to bleeding within 28 days of randomisation occurred in 253
(4.2%) patients in the TXA group and 262 (4.4%) patients in the placebo group (0.97, 95% CI 0.82 to 1.15).
Death from all causes within 28 days of randomisation (Table 4) occurred in 564 patients (9.5%) in the TXA
group and in 548 patients (9.2%) in the placebo group (RR 1.03, 95% CI 0.92 to 1.16).
The proportion of patients with rebleeding was similar in both groups at 24 hours, 5 days and 28 days
after randomisation (see Table 2). The proportion of patients who had surgery, radiological intervention
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Log-rank test p-value = 0.762
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FIGURE 4 Cumulative incidence plot of death due to bleeding. Hazard ratio 0.97, 95% CI 0.82 to 1.16.
TABLE 4 Effect of TXA on all-cause mortality
Cause of death
Treatment group, n (%)
RR (95% CI)TXA (N= 5956) Placebo (N= 5981)
Bleeding 253 (4.2) 262 (4.4) 0.97 (0.82 to 1.15)
Thromboembolic event 26 (0.4) 17 (0.3) 1.54 (0.83 to 2.83)
Organ failure 109 (1.8) 114 (1.9) 0.96 (0.74 to 1.25)
Pneumonia 57 (1.0) 42 (0.7) 1.36 (0.92 to 2.03)
Sepsis 33 (0.6) 49 (0.8) 0.68 (0.44 to 1.05)
Malignancy 65 (1.1) 40 (0.7) 1.63 (1.10 to 2.42)
Other 21 (0.4) 24 (0.4) 0.88 (0.49 to 1.58)
All cause 564 (9.5) 548 (9.2) 1.03 (0.92 to 1.16)
Death in hospital during follow-up.
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The mean number of days spent in intensive care was similar in both groups (Table 6). The mean score
on the Katz Index of Independence in Activities of Daily Living was also similar in both groups
(see Table 6).
Adverse events
The risk of fatal or non-fatal thromboembolic events and arterial thromboembolic events (myocardial
infarction or stroke) was similar in the TXA group and the placebo group (see Table 6). The risk of
venous thromboembolic events (deep-vein thrombosis or pulmonary embolus) was higher in the TXA
group than in the placebo group (see Table 6), and similar risk was observed after excluding patients
who did not receive the maintenance dose (42 events with TXA compared with 20 events with placebo)
(RR 2.11, 95% CI 1.24 to 3.59). In an exploratory subgroup analysis, the risk of venous thromboembolic
events was higher in patients with suspected variceal bleeding or liver disease (14 vs. 2 events; RR 7.26,
95% CI 1.65 to 31.90) than in patients with other causes of bleeding (34 vs. 24 events; RR 1.38, 95% CI
0.82 to 2.32; p = 0.035 for heterogeneity). The risk of renal, hepatic and respiratory failure, cardiac events,
sepsis and pneumonia was similar in TXA- and placebo-treated patients (see Table 6). Seizures occurred
in 38 patients in the TXA group and in 22 patients in the placebo group (0.6% vs. 0.4%; RR 1.73, 95% CI
1.03 to 2.93) (see Table 6); after excluding patients who did not receive the maintenance dose the
corresponding numbers were 33, compared with 17 events (RR 1.95, 95% CI 1.09 to 3.50). See Appendix 7
for a list of all adverse events.
Analyses that are specified in the statistical analysis plan, but not reported above, will be reported in
separate publications.
TABLE 5 Effect of TXA on the need for surgical, endoscopic and radiological interventions or blood product transfusion
Treatment group
Effect size (95% CI)TXA Placebo
Interventions, n/N (%)
Diagnostic endoscopy 4781/5953 (80.3) 4729/5978 (79.1) 1.02 (1.00 to 1.03)a
Therapeutic endoscopy 2542/5952 (42.7) 2658/5978 (44.5) 0.96 (0.92 to 1.00)a
Diagnostic radiological procedure 1704/5953 (28.6) 1744/5978 (29.2) 0.98 (0.93 to 1.04)a
Therapeutic radiological procedure 74/5953 (1.2) 89/5978 (1.5) 0.83 (0.61 to 1.13)a
Surgical intervention 146/5953 (2.5) 158/5978 (2.6) 0.93 (0.74 to 1.16)a
Any surgical, endoscopic or radiological
intervention
5216/5956 (87.6) 5236/5981 (87.5) 1.00 (0.99 to 1.01)a
Any transfusion 4076/5951 (68.5) 4129/5978 (69.1) 0.99 (0.97 to 1.02)a
Whole blood or red cells 3984/4076 (97.7) 4018/4129 (97.3) 1.00 (1.00 to 1.01)a
Frozen plasma 910/4076 (22.3) 993/4129 (24.0) 0.93 (0.86 to 1.00)a
Any platelets 219/4076 (5.4) 255/4129 (6.2) 0.87 (0.73 to 1.04)a
Blood product transfusions, mean (SD)
Units of whole blood or red cells 2.8 (2.4) 2.9 (2.7) –0.06 (0.05 to –0.18)b
Units of frozen plasma 0.9 (2.4) 1.0 (2.6) –0.05 (–0.01 to –0.23)b
Units of any platelets 0.2 (0.9) 0.2 (1.0) –0.02 (0.02 to –0.06)b
a Data are in the form RR (95% CI).
b Data are in the form difference in means (95% CI).
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TABLE 6 Complications and self-care capacity in study groups
Treatment group
Effect size (95% CI)TXA Placebo
Complications, n/N (%)
Any thromboembolic event 86/5952 (1.4) 72/5977 (1.2) 1.20 (0.88 to 1.64)a
Venous events (deep-vein thrombosis,
pulmonary embolism)
48/5952 (0.8) 26/5977 (0.4) 1.85 (1.15 to 2.98)a
Deep-vein thrombosis 23/5952 (0.4) 12/5977 (0.2) 1.92 (0.96 to 3.86)a
Pulmonary embolism 28/5952 (0.5) 16/5977 (0.3) 1.76 (0.95 to 3.24)a
Arterial events (myocardial infarction, stroke) 42/5952 (0.7) 46/5977 (0.8) 0.92 (0.60 to 1.39)a
Myocardial infarction 24/5952 (0.4) 28/5977 (0.5) 0.86 (0.50 to 1.48)a
Stroke 19/5952 (0.3) 18/5977 (0.3) 1.06 (0.56 to 2.02)a
Renal failure 142/5951 (2.4) 157/5978 (2.6) 0.91 (0.73 to 1.14)a
Liver failure 196/5952 (3.3) 184/5977 (3.1) 1.07 (0.88 to 1.30)a
Respiratory failure 105/5952 (1.8) 131/5978 (2.2) 0.81 (0.62 to 1.04)a
Cardiac event 100/5952 (1.7) 89/5977 (1.5) 1.13 (0.85 to 1.50)a
Sepsis 210/5952 (3.5) 216/5977 (3.6) 0.98 (0.81 to 1.18)a
Pneumonia 193/5952 (3.2) 174/5978 (2.9) 1.11 (0.91 to 1.36)a
Seizure 38/5952 (0.6) 22/5977 (0.4) 1.73 (1.03 to 2.93)a
Self-care capacity, mean (SD)
Days in ICU 0.4 (1.8) 0.4 (2.0) –0.06 (0.01 to –0.13)b
Katz score 5.5 (1.5) 5.5 (1.4) –0.03 (0.02 to –0.09)b
a Data are in the form RR (95% CI).
b Data are in the form difference in means (95% CI).
Note
Thromboembolic events and complications are not mutually exclusive.
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Chapter 5 Economic evaluation results
The HALT-IT trial did not demonstrate that TXA significantly reduces key outcome measures, such asdeath due to bleeding within 5 days of randomisation (RR 0.99, 95% CI 0.82 to 1.18) or all-cause
mortality (RR 1.03, 95% CI 0.92 to 1.16), when administered to people with AGIB.This means by default
that, even if it is relatively inexpensive, TXA is unlikely to represent value for money in this indication.
However, we have proceeded with the economic evaluation on the basis that it is important to assess the
level of uncertainty around the cost-effectiveness of TXA based on the data available.
Methods
Decision problem
The analysis evaluates the cost-effectiveness of the current standard of care for people with AGIB with
and without the administration of TXA. The evaluated TXA regimen mirrors that used in the HALT-IT
trial, specifically a TXA loading dose (1 g) added to a 100-ml infusion bag of 0.9% sodium chloride,
infused by slow intravenous injection over 10 minutes, and a TXA maintenance dose (3 g) added to
1 litre of an isotonic intravenous solution, infused over 24 hours.
We followed the NICE technology appraisal guidelines for conducting economic evaluations.68 The
evaluation uses a decision model to combine the clinical results from the HALT-IT trial with evidence
from other sources to estimate costs and outcomes over a lifetime horizon for the two treatment
options. The analysis adopts a UK NHS cost perspective and expresses health outcomes in terms of LYs
and QALYs. Costs are reported in 2017/18 Great British pounds. All future costs and QALYs have been
discounted at an annual rate of 3.5%.
Decision model
We have based our analysis on an existing Markov model of TXA following AGIB to estimate its cost-
effectiveness in the AGIB setting.69 The model consists of two health states, alive and dead, as shown
in Figure 5. People with AGIB enter the model in the alive health state. People in the no-TXA group
progress to the dead health state over the initial 28-day period (the HALT-IT trial period) using daily
data taken directly from the trial on all-cause deaths from the placebo group of the HALT-IT trial; this
includes data for all UK and non-UK participants. For the remaining 337 days of the first year, the
daily probability of death in the no-TXA group was estimated using UK general population age-related
mortality statistics,70 adjusted using a standardised mortality ratio (SMR) to reflect the long-term risk
of excess death associated with surviving an AGIB episode.71 In the base case, this SMR is applied for
the entire time horizon. After this initial 1-year period, the model cycles yearly, applying the same
probability function of death adjusted for the yearly rather than the daily cycle period. In line with the
HALT-IT trial, the mean age of people entering the model was assumed to be 58.1 years.
The SMR associated with the risk of death following an AGIB episode compared with that of the
general population was derived from a study by Crooks et al.,71 in which longitudinal data from the
UK’s Hospital Episodes Statistics data set, the General Practice Research Database and the Office for
National Statistics death register between 1997 and 2010 were linked to define a cohort of people
with non-variceal bleeds. Controls were matched at the start of the study by age, sex, practice and year.
Alive Dead
FIGURE 5 Markov model structure showing both health states in the model.
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Given that the study showed that the risk of death was highest in the first year following an AGIB episode,
separate SMRs were derived for year 1 (SMR 5.21, 95% CI 4.25 to 6.38) and year 2 onwards (SMR 1.74,
95% CI 1.42 to 2.13). In the deterministic sensitivity analysis, excess mortality was excluded after 1 year.
Treatment effect
The base-case cycle probabilities of death in the TXA group were calculated in exactly the same
manner as in the placebo group, but a relative treatment effect was also applied using a RR of
all-cause death of 1.03 (95% CI 0.92 to 1.16); this RR is based on all trial participants and is not UK
specific given that the subgroup analysis did not reveal any differences in treatment effect by country
income level. Note that the HALT-IT trial results for the primary outcome measure, death due to
bleeding within 5 days from randomisation, were similar in both treatment groups (RR 0.99, 95% CI
0.82 to 1.18), although the mean estimate slightly favoured TXA. However, given that the risks of
venous thromboembolic events (deep-vein thrombosis or pulmonary embolus) and death from
malignancy (RR 1.63, 95% CI 1.10 to 2.42) were higher in the TXA group than in the placebo group
(RR 1.85, 95% CI 1.15 to 2.98), the RR of all-cause mortality was used as the estimate of effect, as it
reflects the overall observed relative impact of TXA treatment on survival.
Utilities
Utility data were not collected as part of the HALT-IT trial; therefore, values were sourced from the
existing literature. Only one directly relevant study could be identified: the relatively recent TRIGGER
(Transfusion in Gastrointestinal Bleeding) RCT.72 This trial evaluated the feasibility and safety of a
restrictive compared with liberal RBC transfusion policy for adults admitted to UK hospitals with AGIB.
Between August 2012 and March 2013, almost 950 people were randomised. Similar to the HALT-IT
trial, the trial time horizon was 28 days. Of note, the EuroQol-5 Dimensions, three-level version,
questionnaire73 was administered in the study, and the utility values have been reported in a
separate publication.74
We have taken a relatively simple approach to applying the utility values within the model base case,
although this approach mirrors that used in a previous economic evaluation of TXA.69 Specifically,
individuals who died within the first 28 days were all assigned a utility of 0 over the entirety of this
28-day period. Campbell et al.74 report a mean utility value of 0.735 (95% CI 0.70 to 0.77) for AGIB
survivors on day 28 in the TRIGGER trial. In the base-case analysis, this value was applied to all
participants in both treatment groups, who were alive at day 28, both during the initial 28-day period
and at all times thereafter until death. Note that functional status was measured in the HALT-IT trial
using the Katz Index of Independence in Activities of Daily Living75 either at hospital discharge or in
hospital at day 28; the scores in both groups were similar. An age adjustment was also applied to the
utility value in each cycle using the decrements reported by Kind et al.,76 so that overall utility declined
with age. In a sensitivity analysis, the utility value of 0.735 after 1 year was replaced with age-adjusted
population values, also reported by Kind et al.,76 whereby the utility values after the first year increased
in line with the utility values of the UK’s general population. The latter approach mimics survivors of
AGIB returning to ‘full health’ after 1 year; however, given the high prevalence of comorbidities in this




The resources associated with providing TXA treatment were derived from the HALT-IT trial and by
making a number of assumptions. The total TXA dose (4 g) included the loading and maintenance dose,
for which the total cost was derived from the British National Formulary77 (£12 per patient). The cost of
the equipment for treatment was assumed to include a needle (£0.04), syringe (£0.06), sodium chloride
infusion bag (£0.55) and isotonic intravenous solution (£3.77). To account for the administration time
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of TXA, hourly staff costs were calculated from the Personal Social Services Research Unit costs for
2018.78 The model assumed that a band 5 nurse would take 21 minutes to administer TXA (£12.95),
following the treatment administration and expert guidance used within the economic evaluations of
the CRASH59,69 and WOMAN trials.79 This led to a total TXA treatment and administration cost of
£29.37 per person (Table 7).
Inpatient stay costs during the initial 28 days
Information from the HALT-IT trial was used to derive the costs of inpatient stays during this period.
The total mean length of stay recorded by people receiving TXA was 5.83 days, and by those receiving
placebo it was 5.80 days (Table 8). In both treatment groups, 0.4 of these days were spent in the ICU.
These lengths of stay were multiplied by NHS reference costs for 2017/1880 for non-elective stays to
derive mean hospital costs of £2292 per person for TXA and £2284 per person for no TXA.
Procedures
While in hospital during the 28-day trial period, participants underwent a number of procedures,
including endoscopies, surgery and radiological interventions (see Table 8). The cost of these procedures
by treatment group was calculated using information from the HALT-IT trial, multiplying the probability
that of each procedure being required by the NHS reference cost for 2017/18.80 The mean per-person
procedural cost was £2216 in the TXA group and £2260 in the placebo group.
Transfusions
While in hospital during the initial 28 days, some participants received transfusions of blood/RBCs,
fresh-frozen plasma and platelets (see Table 8). Information from the HALT-IT trial on the frequency
and the mean number of units for each transfusion type were combined with unit costs from the
NHS Blood and Transplant Price List81 to generate overall costs. The mean per-person transfusion cost
was £234 in the TXA group and £245 in the placebo group.
TABLE 7 Base-case model input parameters and their source
Parameter Value 95% CIs Distribution Source
Age at model start (years) 58.1 – – HALT-IT
SMR year 1 5.21 4.25 to 6.38 Log-normal Crooks et al.71
SMR year 2 1.74 1.42 to 2.13 Log-normal Crooks et al.71
RR of all-cause mortality 1.03 0.92 to 1.16 Log-normal HALT-IT
28-day probability of deatha 0.092 0.084 to 0.099 Beta HALT-IT
Utility AGIB survivor 0.735 0.70 to 0.77 Beta Campbell et al.74
Utility decrements by age (years) Kind et al.76
55–64 0 – –
65–74 0.02 – –
≥ 75 0.07 – –
Utility UK general population By age – – Kind et al.76
All–cause mortality By age – – ONS70
Discount rate costs 3.5% – – NICE68
Discount rate QALYs 3.5% – – NICE68
ONS, Office for National Statistics.
a The 28-day risk of death in the placebo group was sampled from a beta-distribution during the probabilistic
sensitivity analysis, based on the proportion of deaths during the trial period (548/5981). The deaths occurring on
each day, as a proportion of the overall 28-day risk, remained the same during sampling.
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TXA administration £29.37 – – British National Formulary,77 assumptions
Inpatient stays to day 28
Total length of stay (days)
TXA 5.83 1.46 Gamma HALT-IT
No TXA 5.80 1.47 Gamma HALT-IT
Days in ICU
TXA 0.4 0.46 Gamma HALT-IT
No TXA 0.4 0.51 Gamma HALT-IT
Unit cost per day in non-ICU £313 – – NHS reference costs80
Unit cost per day in ICU £1479 – – NHS reference costs80
Procedures to day 28
Probability endoscopy: diagnostic
TXA 0.8 4781/5953 Beta HALT-IT
No TXA 0.79 4729/5978 Beta HALT-IT
Unit cost £617 – – NHS reference costs80
Probability endoscopy therapeutic
TXA 0.43 2542/5953 Beta HALT-IT
No TXA 0.44 2658/5978 Beta HALT-IT
Unit cost £721 – – NHS reference costs80
Probability surgical intervention
TXA 0.02 146/5953 Beta HALT-IT
No TXA 0.03 158/5978 Beta HALT-IT
Unit cost £1065 – – NHS reference costs80
Probability radiological diagnostic
TXA 0.29 1704/5953 Beta HALT-IT
No TXA 0.29 1744/5978 Beta HALT-IT
Unit cost £4625 – – NHS reference costs80
Probability radiological therapeutic
TXA 0.01 74/5953 Beta HALT-IT
No TXA 0.01 89/5978 Beta HALT-IT
Unit cost £4625 – – NHS reference costs80
Transfusions
Probability blood or red cells
TXA 0.67 3984/5951 Beta HALT-IT
No TXA 0.67 4018/5978 Beta HALT-IT
Mean units of blood or red cells
TXA 2.80 0.61 Gamma HALT-IT
No TXA 2.90 0.69 Gamma HALT-IT
Unit cost £122 – – NHS Blood and Transplant Price List81
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Post-discharge costs
The HALT-IT and TRIGGER trials observed participants for a maximum of 28 days; therefore, longer-term
care costs were sourced from the literature. A specific study related to AGIB could not be identified.
However, a recent UK study by Ramagopalan et al.82 estimated the costs of GI bleeding among people
with non-valvular atrial fibrillation by comparing the costs in people who were and those who were not
experiencing a bleed, and used a difference-in-difference approach to calculate the costs attributable to
a GI bleed (cases, n = 7753; controls, n = 7753). The controls were matched to cases on a 1 : 1 basis
using a propensity scoring approach and nearest neighbour matching with replacement. Information on
resource use was derived from the Clinical Practice Research Data link and Hospital Episode Statistics,
and included information on primary care, procedures, prescriptions, inpatient stays and outpatient
visits. A matching study used a variety of sources to estimate unit costs in this study, including the
2017/18 NHS reference costs.80
The study allows the annual costs of caring for people with a bleed to be calculated for 3 years after
the date of the bleeding event (see Table 8). In the absence of other information, the reported year 3
costs were inputted to the model for year 4 onwards, although they were assumed to be one-third of
the original amount. The standard errors that the costing study reports could not be easily incorporated
into our analysis (the statistical approach used allowed costs to be negative) and, therefore, were
assumed to be 50% of the mean value in all instances, which is considered to reflect a relatively large
degree of uncertainty in the mean estimates. The importance of these assumptions was assessed in the
sensitivity analysis.





TXA 0.15 910/5951 Beta HALT-IT
No TXA 0.16 993/5978 Beta HALT-IT
Mean units of fresh-frozen plasma
TXA 0.90 0.61 Gamma HALT-IT
No TXA 1.0 0.66 Gamma HALT-IT
Unit cost £28 – – NHS Blood and Transplant Price List81
Probability platelets
TXA 0.04 219/5951 Beta HALT-IT
No TXA 0.04 255/5978 Beta HALT-IT
Mean units of platelets
TXA 0.20 0.23 Gamma HALT-IT
No TXA 0.20 0.26 Gamma HALT-IT
Unit cost £178 – – NHS Blood and Transplant Price List81
Post-discharge costs
Year 1 £3989 £1995a Gamma Ramagopalan et al.82
Year 2 £1816 £908a Gamma Ramagopalan et al.82
Year 3 £1777 £889a Gamma Ramagopalan et al.82
a Standard errors were assumed to be 50% of the mean value in the base-case analysis.
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Subgroup analysis
The HALT-IT trial protocol2 specifies subgroup analyses to examine the effects of TXA on death due to
bleeding within 5 days of randomisation based on time to treatment (≤ 3 vs. > 3 hours), site of bleeding
(upper vs. lower GI), cause of bleeding (suspected variceal bleeding or comorbid liver disease vs. other
or unknown causes) and clinical Rockall score. Post hoc subgroup analyses stratified by World Bank
classification of country income level (high vs. low or middle income), anticoagulant use and SBP were
also undertaken. However, no evidence of heterogeneity was recorded. For this reason, we do not
report any cost-effectiveness results for different AGIB subgroups.
Sensitivity analysis
Various one-way deterministic sensitivity analyses were undertaken to assess the robustness of the
results to alternative assumptions. A probabilistic sensitivity analysis (PSA) was also undertaken using
10,000 Monte Carlo simulations; the parameter distributions are specified in Tables 7 and 8. Risk ratios
were specified as log-normal distributions, utilities and other proportions as beta-distributions and
costs as gamma-distributions. Parameters that were excluded from the PSA are not assigned a
distribution type in the tables.
We report the results as incremental cost-effectiveness ratios (ICERs), incremental net monetary
benefits (INMBs), cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs).
A threshold of willingness to pay for an additional QALY of £20,000–30,000 was used to determine
cost-effectiveness, in line with the NICE technology appraisal recommendations.68
Results
The base-case results are shown in Table 9. In both the deterministic and the probabilistic analyses
TXA was associated with marginally smaller gains in LYs and QALYs, and lower costs, than treatment
without TXA. For example, the deterministic QALYs and costs associated with TXA and no TXA were
8.58 and 8.61, and £16,706 and £16,764, respectively. The associated ICERs are £1413 per LY gained
and £1981 per QALY gained if no TXA is used instead of TXA (i.e. at NICE-recommended threshold
willingness-to-pay values, no TXA is the preferred option). The deterministic and mean probabilistic
results are almost identical (see Table 9).
The lower mean health outcomes for TXA are driven by the fact that the mean RR for all-cause
mortality (i.e. the relative treatment effect inputted to the model) slightly favours the no-TXA treatment
group (RR 1.03). The higher incremental costs associated with no TXA are largely driven by the fact
that people who did not receive TXA live for marginally longer than those who received TXA; thus,
patients who are not treated with TXA incur slightly higher post-discharge costs and marginally higher
intervention and transfusion costs than those who are treated with TXA, and these costs more than
outweigh the additional cost of TXA administration.
TABLE 9 Base-case probabilistic results
Analysis Costs (£) LYs QALYs ICER LYs (£) ICER QALYs (£)
Deterministic
No TXA 16,764 12.08 8.61 1413 1981
TXA 16,706 12.04 8.58 – –
Probabilistic (PSA)
No TXA 16,895 12.21 8.70 1419 1988
TXA 16,840 12.17 8.67 – –
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Various deterministic one-way sensitivity analyses are shown Table 10. In all but one instance the
results show that the base-case ICER was very robust to alternative model parameter and structural
assumptions. The exception is when the RR of all-cause mortality is reduced to 0.92 (the lower
bound of the 95% CI). In this instance, TXA produces marginally better health outcomes at slightly
higher costs than no TXA, producing an ICER of £1144 per QALY gained if TXA is used instead of
no TXA. Note that, even when the cost of TXA and its administration was set to £0 instead of the
base-case value of £29.37, the ICER per QALY gained remained under £3000, favouring no TXA.
The base-case cost-effectiveness plane and CEAC for the probabilistic costs and QALYs are shown in
Figures 6 and 7, respectively. The cost-effectiveness plane shows that the simulations are clustered
around the origin and distributed relatively evenly across all four cost-effectiveness quadrants.
This is because the point estimate for the RR of all-cause mortality is only slightly above 1, and is
included within its CI (RR 1.03, 95% CI 0.92 to 1.16); therefore, there is little to choose between the
two treatment options in terms of outcomes. The same is also true of the relatively low cost of TXA
administration (£29.37 per person), meaning that the majority of the costs incurred are the hospital
costs (hospital stay, interventions and transfusions) and post-discharge costs. The CEAC summarises
the cost-effectiveness plane and shows that at any willingness to pay for an additional QALY above
£2000, no TXA is likely to be the more cost-effective option. For example, at the NICE-specified
willingness-to-pay threshold levels of £20,000 and £30,000 per additional QALY, TXA has a 34% and
33% probability of being the most cost-effective option, respectively. Note that the base-case CEAC














Base case –58 –0.04 –0.03 1413 1981 –524
Excess mortality excluded after
first year
–62 –0.05 –0.03 1306 1843 –611
Monitoring costs (full
monitoring costs for year 4
onwards)
–96 –0.04 –0.03 2357 3304 –486
Monitoring costs not included
beyond 3 years
–38 –0.04 –0.03 941 1319 –544
0% discount rate –70 –0.06 –0.04 1162 1646 –783
6% discount rate –52 –0.03 –0.02 1609 2243 –412
Utility: general population
utility after first year
–58 –0.04 –0.03 1413 1826 –574
Monitoring costs: inpatient
costs excluded in year 1
–49 –0.04 –0.03 1204 1688 –533
TXA all-cause mortality RR
(0.92)
79 0.10 0.07 816a 1144a 1310
TXA all-cause mortality RR
(1.16)
–210 –0.19 –0.14 1080 1514 –2568
Total TXA administration at £0 –87 –0.04 –0.03 2133 2990 –600
a In this scenario, the ICERs flip, meaning that they favour TXA treatment (hence the positive INMBs). INMBs are
calculated using a £20,000 willingness to pay for an additional LY/QALY threshold. Negative costs, LYs and QALYs
indicate that TXA is less costly and less effective than no TXA.
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does not indicate that there is a 0% probability that TXA is the most cost-effective treatment option,
irrespective of the willingness-to-pay value. The lowest that this value can reduce to is 15% because
TXA treatment produced more QALYs at lower cost in this proportion of simulations (i.e. it was the
‘dominant’ treatment option in this proportion of simulations). Re-running the PSA assuming the
standard error of the post-discharge costs to be 20%, instead of 50%, of their mean value had a






















FIGURE 6 Base-case cost-effectiveness plane. The north-east quadrant contains 15% of simulations, the south-west
































FIGURE 7 Base-case CEAC. The north-east quadrant contains 27% of simulations, the south-west quadrant 25%, the
south-east quadrant 24% and the north-west quadrant 24%.
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To demonstrate the sensitivity of the results to alternative parameter values for the RR for all-cause
mortality, the PSA was re-run assuming a RR of 1.00 (95% CI 0.88 to 1.10). These values are somewhat
arbitrary/hypothetical, but include a point estimate that does not favour either treatment, with a
wide CI that still includes a value of 1. Irrespective of the threshold willingness-to-pay level, the
probability of TXA being the most cost-effective option is approximately 50% (Figure 8), demonstrating
































FIGURE 8 Cost-effectiveness acceptability curve assuming a hypothetical RR of all-cause mortality of 1.00 (95% CI 0.88 to 1.10).
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In this trial, TXA did not reduce death from GI bleeding but was associated with an increased risk ofvenous thromboembolic events and seizures. The proportion of patients experiencing rebleeding was
similar in the TXA and placebo groups.
Administration of TXA within 3 hours of bleeding onset reduces death due to bleeding in patients
with trauma or post-partum haemorrhage without increasing the risk of thromboembolic events. In these
bleeding scenarios, the timing of onset is easy to determine: most patients present early and there are well-
documented changes in fibrinolysis that provide a biological rationale for TXA treatment.83,84 However, in
the case of GI bleeding it is difficult to determine the time of bleeding onset, presentation is often delayed
(> 80% of patients present > 3 hours after bleeding onset) and the contribution of increased fibrinolysis to
bleeding is less clear.
Almost half of the patients included in our trial had suspected variceal bleeding due to liver disease,
and because these patients have a greater risk of death they accounted for nearly three-quarters of
deaths. Recent research shows that acutely ill patients with cirrhosis have amixed fibrinolytic phenotype.85
Some have increased fibrinolysis but others have profound hypofibrinolysis.The prevalence of hypofibrinolysis
appears to be greatest in the most critically ill patients. Using the same clot lysis assay, reduced fibrinolysis
has been shown to be associated with a small increased risk of venous thrombosis.86 In our trial, the
increased risk of venous thromboembolic events with TXA appeared to be more marked in patients with
liver disease, although this was an exploratory subgroup analysis and there was no strong evidence of
heterogeneity. Nevertheless, reduced fibrinolysis in patients with liver disease might explain the lack of
any reduction in bleeding deaths with TXA and the increased risk of venous thromboembolic events.
The dose of TXA used in this trial was higher and the duration of treatment was longer (4 g over 24 hours)
than that in randomised trials of TXA in trauma54,57 (2 g over 8 hours) or post-partum haemorrhage55
(1-g bolus with a repeat 1-g dose if bleeding continued), which did not record any increase in adverse
events with TXA. Patients with GI bleeding often rebleed after initial haemostasis, particularly within the
first 24 hours. Because TXA has a short half-life, we used a longer treatment duration to cover this high-
risk period. Furthermore, previous trials in GI bleeding that appeared to show a large mortality reduction
with TXA used a high dose and a longer duration of treatment than trials in trauma and post-partum
haemorrhage.87 The longer duration of TXA treatment in this trial may explain the increased risk of venous
thromboembolic events, and the higher dose may explain the increased risk of seizures.88
In summary, we found no evidence that TXA decreases the risk of death in patients with GI bleeding.
Our results caution against a uniform approach to the management of patients with major haemorrhage
and highlight the need for randomised trials targeted at specific pathophysiological processes. Given that
GI bleeding is a licensed indication for TXA, our results may have regulatory implications.
Strengths and limitations
Our trial had several strengths but also some limitations. The randomisation method ensured that
participating clinicians had no foreknowledge of the treatment allocation and the placebo control
ensured that the outcome assessment was blind to treatment group. The inclusion criteria were clinical,
reflecting the full range of GI bleeding presentations that doctors face in day-to-day practice. Baseline
prognostic factors were well balanced and almost all randomly assigned patients were followed up.
The primary outcome was death due to bleeding within 5 days of randomisation. Our scientific reasons
for prespecifying death due to bleeding as the primary outcome in the statistical analysis plan are
presented in detail elsewhere.67 Although some misclassification of cause of death is possible, the
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assessment was blind to the treatment group. However, as there was no evidence of a treatment effect
for the prespecified primary end point (death due to bleeding at 5 days) or for death from any cause at
28 days, the choice of end point does not influence the interpretation of the results. Misclassification might
also have affected our subgroup analyses because at the time of recruitment the site and cause of bleeding
could not be known with certainty. Our use of the pre-endoscopy Rockall score may have misclassified the
baseline risk.89 To minimise the risk of false positives, we used strict criteria to diagnose thromboembolic
events, including a positive result on imaging (e.g. ultrasound) or at post-mortem examination. Although
this may have led to some under-reporting because the diagnostic tests have high specificity, the RR
estimates should be unbiased. Although some patients received antifibrinolytics outside the protocol,
the treatment effect was the same when these patients were excluded. Although this is one of the
largest randomised trials in GI bleeding, we cannot rule out a modest increase or decrease in death due
to bleeding with TXA. However, we can rule out the large mortality reduction suggested by the Cochrane
systematic review and meta-analysis of previous small trials.87
Cost-effectiveness
The results of the analysis suggest that the costs and outcomes of treating people with AGIB with and
without TXA, as enrolled and treated in the HALT-IT trial, are very similar. However, the base-case
probabilistic analysis showed that the probability that TXA is the most cost-effective option is 34% and
33% at thresholds of willingness to pay for an additional QALY of £20,000 and £30,000, respectively.
This means that, on balance, no TXA is more likely to be the most cost-effective option. The deterministic
sensitivity analyses confirmed the robustness of this finding. These results are in line with our prior
expectations given the additional, albeit modest cost (£29.37), of providing TXA and the knowledge that
it was not associated with a statistically significantly reduction in all-cause mortality (RR 1.03, 95% CI
0.92 to 1.16), as reported by the HALT-IT trial.
As with all decision models, our analysis includes a number of parameter and structural assumptions.
For example, assumptions were made regarding the longer-term costs of caring for people who
recover from an initial episode of AGIB, and the utility values were sourced from outside the HALT-IT
study and were assumed to be equal for both treatment groups. Moreover, unlike previous economic
evaluations of TXA, we estimated the impact of treatment based on a RR of all-cause mortality
rather than death due to bleeding, given that TXA was associated with a higher risk of death due to
thromboembolic events and malignancies. However, only the scenarios that included a point RR of
all-cause mortality favouring TXA over no TXA resulted in TXA being considered the most cost-effective
option. We therefore do not believe that any of the assumptions that have been made, or the use of
alternative measure of treatment effect, are of particular importance in terms of affecting the overall
conclusions regarding cost-effectiveness.
To the best of our knowledge, no other cost-effectiveness analyses of TXA for people with AGIB have
been reported. However, economic evaluations based on the series of CRASH RCTs57 and theWOMAN
RCT55 concluded that TXA is highly cost-effective in other indications, specifically following trauma injury69
and post-partum haemorrhage.79 The dose of TXA used in the HALT-IT trial is higher than that used in the
previous studies. However, the increased cost of treatment is negligible and does not explain the clearly
different cost-effectiveness results. The basic reason for the difference is that the HALT-IT trial did not
provide any evidence to support a statistically significant improvement in health outcomes from using TXA,
whereas evidence of benefit was much stronger in the other indications. However, 80% of participants in
the HALT-IT trial received treatment > 3 hours after the suspected onset of bleeding. This is important
because there is reason to believe from the RCTs of TXA in trauma and post-partum haemorrhage that
earlier treatment is associated with improved outcomes. Our cost-effectiveness results reflect the timing
of treatment as given in the HALT-IT trial, meaning that we cannot rule out the possibility of TXA being
the most cost-effective option if treatment is more promptly administered.
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Findings in context
Evidence before this study
Before this study, a Cochrane systematic review and meta-analysis87 of randomised trials of TXA for
upper GI bleeding included seven trials with a total of 1654 patients. There was a large reduction in
mortality with TXA (pooled RR 0.61, 95% CI 0.42 to 0.89; p = 0.01).87 However, given the small size of
the included trials and the potential for selection and other biases, we considered this evidence to be
hypothesis-generating, requiring confirmation in larger trials. Furthermore, there was substantial
uncertainty about the risk of thromboembolic events with TXA (pooled RR 1.86, 95% CI 0.66 to 5.24).
Added value of this study
The HALT-IT trial included 12,009 patients from 164 hospitals in 15 countries. Adult patients with
significant upper or lower GI bleeding were randomly assigned to receive TXA (a 1-g loading dose
followed by a 3-g maintenance dose over 24 hours) or matching placebo. TXA did not reduce death
from GI bleeding (RR 0.99, 95% CI 0.82 to 1.18) but was associated with an increased risk of venous
thromboembolic events (RR 1.85, 95% CI 1.15 to 2.98) and seizures (RR 1.73, 95% CI 1.03 to 2.93).
Implications of all the available evidence
The most recent update of the Cochrane review included eight small randomised trials with 1701
participants and showed a reduction in mortality with TXA (RR 0.60, 95% CI 0.42 to 0.87). Although
we cannot entirely rule out a modest increase or decrease in death due to bleeding with TXA, we can
rule out the large mortality reduction suggested by the Cochrane review.60 Furthermore, TXA appears
to increase the risk of venous thromboembolic events in patients with GI bleeding. On the basis of our
results, TXA should not be used for the treatment of GI bleeding outside the context of a randomised
trial. Our results highlight the unreliability of meta-analyses of small trials.
Implications for practice in the NHS
Many emergency physicians and surgeons believe that TXA improves outcomes in patients with acute
severe GI bleeding. Emergency physicians and surgeons are familiar with TXA, which is widely used in
trauma and elective surgery based on compelling evidence from large, high-quality, randomised trials.
The promotion of ‘major haemorrhage protocols’ in UK hospitals encourages the notion that all
bleeding is fundamentally the same and can be treated in a similar way. Furthermore, the Cochrane
systematic review and meta-analysis87 of previous trials of TXA in GI bleeding shows a large reduction
in mortality with TXA (pooled RR 0.61, 95% CI 0.42 to 0.89; p = 0.01). Despite the small size of the
included trials, the potential for selection and other biases and the lack of data on adverse effects
suggest that these results should be seen as hypothesis-generating rather than confirmatory; these
methodological caveats can be lost on a doctor struggling to control a life-threatening GI bleed. Indeed,
even the methodologically sophisticated NIHR Health Technology Assessment (HTA) Commissioning
Board questioned the need for the HALT-IT trial given the evidence from the Cochrane review.
‘The Board expressed significant concerns about the need of this trial in the light of current evidence for
benefit for TXA in GI bleeding and other conditions. Therefore, the applicants should argue the case for
this trial very thoroughly in their full application.’ (NIHR, 2011, personal communication).
The results of the HALT-IT trial showed that TXA did not reduce death from GI bleeding but was
associated with an increased risk of venous thromboembolic events and seizures. The proportion of
patients with rebleeding was similar in the TXA and placebo groups. These results caution against a
‘one size fits all’ approach to the management of patients with major haemorrhage and highlight the
need for randomised trials targeted at specific pathophysiological processes. In traumatic bleeding, the
timing of bleeding onset is easy to determine: most patients present early and there are well-documented
changes in fibrinolysis that provide a biological rationale for TXA treatment. However, in the case of GI
DOI: 10.3310/hta25580 Health Technology Assessment 2021 Vol. 25 No. 58
Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
39
bleeding, it is difficult to determine the time of bleeding onset, presentation is often delayed (> 80% of
patients present more than 3 hours after bleeding onset) and the contribution of increased fibrinolysis to
bleeding is less clear. Based on the HALT-IT trial results, TXA should not be used for the treatment of GI
bleeding outside the context of a randomised trial.
Implications for research in the NHS
Although we cannot rule out a modest increase or decrease in the risk of death due to bleeding with
TXA, we can rule out the large mortality reduction suggested by the Cochrane systematic review
and meta-analysis87 of previous small trials. In this respect, the HALT-IT trial highlights the dangers of
overinterpreting results from systematic reviews of small trials. Although the review authors emphasised
the methodological weakness of the included trials, pointing out the ‘limitations in their internal and
external validity’, the large, statistically significant reduction in all-cause mortality is hard to ignore and
has had a considerable impact on research on this topic. As previously stated, the HTA Board questioned
the need for a trial given the systematic review evidence. The large mortality reduction also made it
harder to justify a large randomised trial. The investigators sent the trial protocol to The Lancet for peer
review. The Lancet reviewers’main concern was that the HALT-IT trial was unnecessarily large.The possibility
that systematic reviews of small trials could cause research waste by encouraging underpowered trials
was raised by the chief investigator in 2015:90
Systematic reviews of small trials increase waste by advertising to the scientific community inflated, often
significant treatment effects that become smaller or absent when large, high-quality trials are done. Effect
estimates from systematic reviews often inform sample size calculations. However, because most reviews
provide exaggerated estimates of treatment effects due to inclusion of small, poor-quality trials, new trials
will be underpowered to detect modest but potentially important effects.
Reproduced with permission from Roberts and Ker90 © Elsevier 2015
Although it is hard to quantify the impact of the Cochrane review on clinical equipoise on this topic,
open-label use of TXA was a recurrent problem in the UK and led to the closure of recruitment to the
HALT-IT trial at many UK hospitals. Had it not been for brisk recruitment in the non-UK hospitals,
the HALT-IT trial may not have achieved its recruitment target. The large discrepancy between the
results of the Cochrane review and the results of the HALT-IT trial should encourage a reconsideration
of the role of systematic reviews of small trials in informing health care and health research. Most
meta-analyses are dominated by small trials. The median number of trials in Cochrane reviews is six,
and the median number of patients per trial is approximately 80.91 In most cases, the results of such
reviews should be considered hypothesis-generating, requiring confirmation in adequately powered
randomised trials.
Despite that, with 12,000 patients, the HALT-IT trial is, to the best of our knowledge, the largest
randomised trial of TXA in GI bleeding, we cannot rule out a modest treatment benefit. Because there
is strong evidence that TXA reduces bleeding deaths in patients with traumatic and post-partum
haemorrhage, individual patient data meta-analyses should assess the strength of the evidence that
the effectiveness and safety of TXA vary by the site and cause of bleeding. Basic research could also
inform this question by examining the role of fibrinolysis in patients with GI bleeding and whether or
not this varies depending on the aetiology of the bleeding.
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Chapter 7 Dissemination
A dissemination plan (see Appendix 8) was written to guide the dissemination of the study results.This document outlined the background to the trial, objectives of the dissemination strategy and
planned specific outputs of dissemination.
Objectives
A key objective of the dissemination plan was to inform the trial collaborators of the HALT-IT trial
results and to help them to disseminate the results in their countries. The successful completion of the
trial was entirely dependent on the work of collaborators in the participating hospitals. Hence, the
results of the trial were reported first to trial collaborators.
Developing dissemination tools that collaborators could use for national and international audiences
helped to achieve this. The various dissemination documents were uploaded onto the trial website to
allow collaborators to download these resources and use them locally. Further dissemination tools for
collaborating investigators were created to help them raise awareness of the trial results.
Dissemination of the results to all trial participants, particularly those who asked to be informed of the
trial results, was also a vital objective. A lay summary of the results was sent to sites to communicate
the results to their participants directly, and wider dissemination to participants took place via the media
and the trial website (URL: https://haltit.lshtm.ac.uk/). The dissemination plan also aimed to make the
results accessible to the public by using social media [including Twitter (Twitter, Inc., San Francisco,
CA, USA; www.twitter.com), Facebook (Facebook, Inc., Menlo Park, CA, USA; www.facebook.com) and
WhatsApp (Facebook, Inc.; www.whatsapp.com), the trial website (https://haltit.lshtm.ac.uk/), the
LSHTM Clinical Trial Unit (CTU) website (https://ctu.lshtm.ac.uk/) and by broadcasting the results in
The Resus Room podcast.
In terms of the scientific and medical community, the objective was to disseminate the results as
widely as possible through publication of the results in a peer-reviewed medical journal, through
conference presentations, by sharing the link to the publication in all applicable trial registers and by
posting the dissemination materials on the HALT-IT website, on the LSHTM CTU website and on social
media. Following completion of all prespecified analyses, another key dissemination objective was to
share individual de-identified patient data, including data dictionary via the LSHTM CTU data-sharing
platform, The Free Bank of Injury and Emergency Research Data (freeBIRD) at https://freebird.lshtm.
ac.uk. The purpose of this was to allow maximum utilisation of the data to improve patient care and
advance medical knowledge.
Outputs
l The trial results were published in The Lancet on 20 June 2020.3
l All trial collaborators, regardless of whether or not their site recruited participants, were sent a
copy of the publication in The Lancet, a PowerPoint presentation containing the trial results and
the social media dissemination pack, enabling them to disseminate the trial results in their own
hospitals and countries.
l Links to The Lancet publication were made available in all applicable trial registers, the HALT-IT trial
website and the LSHTM CTU website.
l A PowerPoint presentation of the results was made available for use by doctors and other
health-care professionals.
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l The results were disseminated to patients via social media (LSHTM CTU Twitter account
@CTU_LSHTM and the LSHTM CTU Facebook page) and the trial website (URL: haltit.lshtm.ac.uk).
l A lay summary of the results was provided to sites to be shared with trial participants.
l A social media dissemination pack was created for dissemination of the trial results and other
dissemination tools on social media.
l The trial website was upgraded to ensure that trial-related dissemination materials could be
downloaded by investigators and others and used for dissemination.
l A podcast with the breakdown of the trial results and an interview with Professor Ian Roberts was
recoded with The Resus Room (@TheResusRoom).
l The trial protocol, statistical analysis plan and trial publication are all freely available online.
l Following completion of all prespecified analyses, totally anonymised trial data will be shared via the
LSHTM CTU data-sharing platform at freebird.lshtm.ac.uk. This will allow for maximum utilisation of
the data to improve patient care and advance medical knowledge.
The impact of COVID-19
It is important to note that the trial results were published during the COVID-19 pandemic, and this
limited the impact of our dissemination plan. As a result of the pandemic, both printed and broadcast
media were, justifiably, almost entirely focused on COVID-19 and, therefore, there was no room for
reporting non-COVID-related research. Unfortunately, this resulted in less coverage than was expected
in the general media and we were unable to use the media to reach a wider audience with these
important results.
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Chapter 8 Reflections and concluding remarks
The HALT-IT trial was one of the largest clinical trials in GI bleeding ever conducted. It found noevidence that TXA reduces deaths from stomach bleeding, but there was evidence that TXA may
increase the risk of thromboembolic events (deep-vein thrombosis or pulmonary embolism). There
were also more seizures with TXA and rebleeding was similar in both groups.
In 2010, the CRASH-2 trial,54 a large multicentre randomised trial of TXA in trauma patients, found
that this inexpensive, generic drug reduces the number of deaths by one-sixth. Following these
results, the team at LSHTM CTU wondered whether or not TXA could have a similar effect in GI
bleeding. The Cochrane review found a surprisingly large (40%) reduction in gastric bleeding deaths;
however, this review was based on the results of a number of smaller trials. To determine whether
or not TXA cuts gastric bleeding deaths, a large trial was needed, and the LSHTM CTU team began
work on the HALT-IT trial.
Initially, NIHR questioned the need for a trial because of the Cochrane review. Even during the trial,
many UK doctors would recruit bleeding patients, randomly allocate them to TXA or placebo but, if
they continued bleeding, would give them TXA regardless. As a result, many UK hospitals were closed
to recruitment owing to lack of clinical equipoise; without strong recruitment from non-UK hospitals,
particularly in Pakistan, we would have failed to reach our recruitment target. The discrepancy between
the results of the Cochrane review and the results of the HALT-IT trial is alarming, but not unusual.
It should prompt a reconsideration of the role of systematic reviews in informing UK health care.
The funders originally requested a 1-year follow-up on the patients randomised in the UK; however,
the follow-up period for these patients was 28 days. The LSHTM CTU team requested access to 1-year
follow-up data from the NHS Health and Social Care Information Centre (now NHS Digital). After the
protocol was finalised in 2014, the NHS Health and Social Care Information Centre requested changes
in the patient information sheet and consent form as a condition of sharing its data. This allowed the
data to be released in 2015. However, in 2016 the policy changed again, and data-sharing was refused.
These results also demonstrate that TXA should not be used for the treatment of GI bleeding outside
the context of a randomised trial, and caution against the use of generic ‘major haemorrhage protocols’
in the UK. Although it is often assumed that a treatment that works in one bleeding situation, such as
traumatic bleeding or post-partum haemorrhage, will probably work in another, these results highlight
the need for clinical trials that target specific causes of bleeding. Patients with GI bleeding may respond
differently to those with traumatic and post-partum bleeding. In particular, patients with underlying
liver disease may be more prone to side effects from unwanted clotting. GI bleeding is currently a licensed
indication for TXA and, therefore, our results could have regulatory implications.
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Appendix 1 HALT-IT trial organisation
Trial Steering Committee
Christopher Hawkey (chairperson), Adefemi Afolabi, Jack Cuzick, Kenneth Halligan
(patient representative), David Henry, Chris Metcalfe and Ian Roberts.
Data Monitoring and Ethics Committee
Richard Gray (chairperson), Alan Barkun, Suresh David, Philip Devereaux and Tony Brady
(independent statistician).
Protocol Committee
Ian Roberts, Haleema Shakur-Still, Timothy Coats, Phil Edwards, Ian Gilmore, Vipul Jairath,
Katharine Ker, Daniela Manno, Simon Stanworth and Andrew Veitch.
Trial Co-ordinating Centre Team
Clinical Trials Unit
Monica Arribas (trial manager/research assistant), Emma Austin (assistant trial manager), Kiran Bal
(assistant trial manager), Eni Balogun (trial manager), Collette Barrow (trial administrator), Danielle Beaumont
(senior trial manager/research fellow), Myriam Benyahia (CTU administrator), Amy Brenner (research fellow),
Imogen Brooks (trial assistant 2016–18), Madeleine Cargill (data assistant), Laura Carrington (trial
administrator), Phil Edwards (statistician 2012–16), Lauren Frimley (trial manager/research assistant),
Amber Geer (assistant data manager), Daniel Gilbert (data assistant 2012–13), Catherine Gilliam (trial
administrator), Julio Gil Onandia (clerical assistant), Nayia Golfi (trial manager 2013–15), Daniel Hetherington
(trial assistant 2012–15), Courtenay Howe (CTU administrator 2015–17), Carolyn Hughes (data assistant
2016–17), David I’anson (assistant trial manager 2016–17), Rob Jackson (data manager 2012–15),
Miland Joshi (statistician 2016–17), Sneha Kansagra (assistant trial manager 2016–18),Taemi Kawahara
(senior trial manager 2012–15), Katharine Ker (lecturer), Sergey Kostrov (systems officer 2015–19),
Daniela Manno (clinical lecturer 2012–15), Raoul Mansukhani (medical statistician 2019–20), HakimMiah
(IT systems manager 2013–19), Bernard Ndungu (assistant trial manager 2016–17), Kelly Needham
(statistician 2018–20), Aroudra Outtandy (trial assistant 2013–15), Daniel Pearson (data assistant
2018–19), Tracey Pepple (acting senior data manager 2014–19), Danielle Prowse (assistant data
manager), Nigel Quashi (data manager 2013–16), Anna Quinn (data assistant 2013–15), Maria Ramos
(senior project administrator 2012–15), Laura Ranopa (trial assistant 2015–20), Mia Reid (clerical
assistant 2016–18), Ian Roberts (chief investigator/CTU co-director), Chris Roukas (trial administrator
2013–15), Haleema Shakur-Still (project director/CTU co-director), Chelci Squires (trial assistant
2014–16), Jemma Tanner (clinical trials associate 2013–16), Andrew Thayne (data assistant) and
Ruhama Uddin (trial assistant 2018–19).
Rawalpindi Medical University Pakistan National Co-ordinating Centre Team
Rizwana Chaudhri (co-ordinating centre director), Muttiullah Mutti (clinical lead), Kiran Javaid
(assistant research co-ordinator) and Aasia Kayani (research co-ordinator).
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Nigeria Co-ordinating Team, University College Hospital Ibadan
Bukola Fawole (co-ordinating centre director), Folasade Adenike Bello (co-ordinating centre director),
Oladapo Olayemi (co-ordinating centre director), Adefemi Afolabi (national principal investigator),
Olujide Okunade (assistant trial co-ordinator) and Olusade Adetayo (assistant trial co-ordinator).
National Co-ordinators
Rizwana Chaudhri (Pakistan), Muttiullah Mutti (Pakistan), Adefemi Afolabi (Nigeria), Folasade Adenike
Bello (Nigeria), Bukola Fawole (Nigeria), Oladapo Olayemi (Nigeria), Hussein Khamis (Egypt),
Mohammad Shukri Bin Jahit (Malaysia), Tamar Gogichaishvili (Georgia), Radu Bogdan Mateescu
(Romania), Ajay Adhikaree (Nepal), Abdelmounem Eltayeib Abdo (Sudan), Mohammad Zaher (Saudi Arabia),
Conor Deasy (Ireland), Joaquin Alvarez Gregori (Spain), Bobby Wellsh (Papua New Guinea) and
Luke Lawton (Australia).
HALT-IT Trial Collaborators by country
UK (n = 4751)
Royal Stoke University Hospital (n= 303)
Raghavendra Kamath, Adrian Barry, Racquel Carpio, Kay Finney and Holly Maguire.
Queen’s Medical Centre Campus Nottingham (n= 208)
Martin James, Frank Coffey, Chris Gough, Lisa Sawers and Aye-Aye Thi.
Royal Berkshire Hospital (n= 191)
Jonathan Simmons, Claire Burnett, Nicola Jacques and Victoria Murray.
St George’s Hospital (n= 173)
Richard Pollok, Heather Jarman, Christine Lambe and Sarah Rounding.
Blackpool Victoria Hospital (n = 166)
Simon Tucker, Romaih Al-Idari, Samuel Guest and Emma Stoddard.
Queen Elizabeth Hospital Birmingham (n= 150)
David Yeo, Colin Bergin, Elaine Hardy and Joanne Thunder.
University Hospital Coventry (n= 128)
Paul Jhalli, Edward Hartley, Catherine Jarvis and Carly Swann.
Royal Infirmary of Edinburgh (n = 125)
Matthew Reed, Bernadette Gallagher, Julia Grahamslaw and Rachel O’Brien.
Royal London Hospital (n= 125)
Timothy Harris, Geoffrey Bellhouse, Olivia Boulton and Imogen Skene.
Glasgow Royal Infirmary (n= 120)
Adrian Stanley, Janet Johnstone, Donogh Maguire and Susan Thornton.
University College London Hospital (n = 113)
Matthew Banks, Georgia Bercades, Daniel Marks and Jung Ryu.
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Whipps Cross University Hospital (n= 108)
Timothy Harris, Claire Dowty, Jason Pott and Imogen Skene.
John Radcliffe Hospital (n = 107)
James East, Adam Bailey, Sally Beer and Sian Davies.
Royal Devon & Exeter Hospital (n= 97)
Andrew Appelboam, Daisy Mackle and Jennifer Small.
Queen Alexandra Hospital Portsmouth (n = 88)
Christiane Vorwerk, Rachel Atkins and Isobel Bradbury.
Leicester Royal Infirmary (n = 84)
Timothy Coats, Catriona Bryceland and Lisa McClelland.
Salford Royal Hospital (n= 83)
Martin Thomas, Kate Clayton and Angiy Michael.
Great Western Hospital (n= 80)
Stephen Haig, Saif Al-Nahhas and Tim Godfrey.
Southampton General Hospital (n = 80)
Philip Boger, Rachel Comer and Barbara Watkins.
Darlington Memorial Hospital (n = 79)
Ola Afolabi, Shazad Afzal and Amanda Cowton.
St James University Hospital Leeds (n = 79)
Simon Everett, Ruth Fazakerley and Felicia Onoviran.
Poole Hospital (n= 77)
Jonathon Snook, Jackie Berry and Diane Simpson.
King’s College Hospital (n = 73)
Jeff Keep, Hannah Cotton and Sinead Helyar.
University Hospital of North Tees (n = 73)
Matthew Rutter, Tracey Johnston and Laura O’Rourke.
Basingstoke and North Hampshire Hospital (n= 72)
Louisa Chan, Joanna Tambellini and Dawn Trodd.
Dorset County Hospital (n= 68)
James Shutt, Sarah Moreton and Abby Oglesby.
Addenbrooke’s Hospital (n = 67)
Adrian Boyle, Nicola Haeger and Susie Hardwick.
Southmead Hospital (n= 67)
Jason Kendall, Beverley Faulkner and Ruth Worner.
Royal Victoria Infirmary (n = 64)
Sarah Hearnshaw, Mary Doona and Maria Price.
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St Thomas’ Hospital (n = 64)
Laura Hunter, Maggie Bell and Vania Loureiro.
Derriford Hospital (n = 61)
Anthony Kehoe, Alison Jefferey and Rosalyn Squire.
Ipswich Hospital (n= 60)
David Hartin, Stephanie Bell and Alexandra Newman.
Musgrove Park Hospital (n = 59)
James Gagg, Jayne Foot and Sue Wakeford.
Royal Oldham Hospital (n = 58)
Gabrielle May, Thomas Bartram and Paul Cumpstay.
Whittington Hospital (n= 58)
Lucy Parker, Rita Das and Sheik Pahary.
Basildon University Hospital (n = 57)
Gavin Wright, Georgina Butt and Natasha Christmas.
Wexham Park Hospital (n = 56)
Sarah Wilson, Mohammed Ashfaq and Louise Chandler.
Royal United Hospital Bath (n= 50)
Saif Al-Nahhas, Carrie Demetriou and Philip Kaye.
Manchester Royal Infirmary (n= 48)
Simon Carley and Andrew Brown.
Chesterfield Royal Hospital (n = 44)
Lucy Jones and Amanda Whileman.
James Cook University Hospital (n= 44)
John Greenaway and Julie Tregonning.
Newham University Hospital (n= 44)
Timothy Harris and Geoffrey Bellhouse.
Northern General Hospital (n= 44)
Avril Kuhrt and Steve Goodacre.
Royal Shrewsbury Hospital (n= 43)
John Jones and Charlotte Owen.
Charing Cross Hospital (n = 41)
Anu Mitra and Abby Harper-Payne.
Sandwell General Hospital (n = 37)
Nigel Trudgill and Anne Hayes.
South Tyneside District Hospital (n = 36)
Faheem Butt and Gayle Clifford.
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Victoria Hospital, Fife (n = 35)
Andrew Kinnon and Susan Fowler.
Chelsea and Westminster Hospital (n = 34)
Kris Pillay and Shweta Gidwani.
Queen Elizabeth Hospital Woolwich (n= 34)
Alistair McNair and Omer Omer.
Gloucestershire Royal Hospital (n = 31)
Tanya de Weymarn and Adnan Amin.
Royal Hampshire County Hospital (n= 31)
Louisa Chan and Jane Martin.
Torbay Hospital (n = 31)
Nick Mathieu and Simon Barnes.
York Hospital (n = 31)
James Turvill and Helen Sweeting.
University Hospital Crosshouse (n= 29)
Morten Draegebo and Marion McNaught.
Worthing Hospital (n = 29)
Mandy Grocutt and Jordi Margalef.
Barnsley Hospital (n= 27)
Julia Humphrey and Richard Jackson.
North Devon District Hospital (n = 27)
Fionn Bellis and Jane Hunt.
St Mary’s Hospital (n= 24)
Anu Mitra.
University Hospital Ayr (n= 22)
Alastair Stevenson.
King’s Mill Hospital (n= 19)
Nicholas Watson.
Royal Sussex County Hospital (n= 19)
Steven Barden.
Forth Valley Royal Hospital (n= 16)
Stuart Paterson.
New Cross Hospital (n = 16)
Andrew Veitch.
Cumberland Infirmary Hospital (n= 14)
Chris Macdonald.
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Sunderland Royal Hospital (n = 14)
David Hobday.
West Cumberland Hospital (n= 13)
Olu Orugun.
Yeovil District Hospital (n= 13)
Andrew Allison.
Northampton General Hospital (n= 12)
Tristan Dyer.
Royal Lancaster Infirmary (n= 12)
Samuel McBride.
Royal Liverpool University Hospital (n = 12)
Wojciech Sawicki.
Hull Royal Infirmary (n= 10)
Ben Rayner.
Frimley Park Hospital (n = 8)
Lynsey Flowerdew.
Queen Elizabeth Hospital – Gateshead (n= 7)
Jamie Barbour.
Salisbury District Hospital (n = 7)
Jason Klein.
Aintree University Hospital (n = 6)
Stephen Hood.
University Hospital of Wales (n = 5)
Nicola Palmer.
Northwick Park Hospital (n= 4)
Jacob de Wolff.
Colchester General Hospital (n= 3)
Achuth Shenoy.
Birmingham City Hospital (n= 2)
Nigel Trudgill.
Royal Bournemouth Hospital (n= 1)
Peter Swallow.
University Hospital Lewisham (n = 1)
Rajaventhan Srirajaskanthan.
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Pakistan (n = 4420)
King Edward Medical University, Mayo Hospital Lahore (n = 539)
Irshad Hussain, Hamza Arshad, Naeem Aslam, Anam Bangash, Muhammad Qamar and Haroon Zahoor.
Rawalpindi Medical University Pakistan, Holy Family Hospital, Unit II (n = 501)
Muttiullah Mutti, Saba Arshad, Quratul ain Ghalib, Tehseen Hameed, Tayyaba Saif and Wajahat Shafi.
Services Institute ofMedical Sciences/Services Hospital GI/Medical Unit III Lahore (n= 443)
Muhammad Arif Nadeem, Abid Ali, Shehroze Khan, Muhammad Muaaz and Ahmad Taj.
Lady Reading Hospital (n= 386)
Aamir Ghafoor, Aamir Afridi, Mansoor Ahmad, Mujahid Aslam and Sandeep Kumar.
Asian Institute of Medical Sciences (n = 360)
Majid Soomro, Mohsin Ali, Ubedullah Bughio, Adil Chang and Sana Shaikh.
Jinnah Postgraduate Medical Centre Karachi (n = 296)
Syed Ahmad, Zeeshan Ali, Marium Waqar, Aiman Mushir and Sadaf Sattar.
DHQ Teaching Hospital Sargodha (n = 207)
Saifullah Goraya, Sharmeen Aslam, Nighat Fatima, Saadia Noreen and Sheraz Saleem.
Rawalpindi Medical University Pakistan, Benazir Bhutto Hospital Unit I (n= 196)
Fazal Rahman, Nadeem Iqbal, Mohammad Khalid and Umar Riaz.
Rawalpindi Medical University Pakistan, Holy Family Hospital, Unit I (n = 169)
Muhammad Umar, Tayyab Akhter, Javaria Khan and Noureen Misbah.
Aziz Bhatti Shaheed Teaching Hospital (n= 160)
Muhammad Afzal, Mobeen Kayani, Syed Shah and Shahida Tarar.
Bolan Medical Complex Hospital (n= 149)
Sherbat Khan, Yasir Iqbal, Essa Khan and Maqbool Reki.
Rawalpindi Medical University Pakistan, Benazir Bhutto Hospital Unit II (n= 120)
Tanveer Hussain, Shafqat Iqbal, Muhammad Khurram and Muhammad Shafi.
Ghulam Muhammad Mahar Medical College and Teaching Hospital Unit I (n = 120)
Abrar Shaikh, Aijaz Ahmed, Ameet Kumar and Pinkey Sachdev.
Jinnah Hospital Unit I (n= 88)
Khalid Mahmood Nasir, Zafar Iqbal Chaudhry and Muhammad Zubair.
Lahore General Hospital Medical Unit I (n= 84)
Ghias Tayyab, Junaid Mushtaq and Muhammad Nasir.
Mardan Medical Complex and Teaching Hospital (n = 80)
Amir Khan, Amjad Ali and Sajjad Ali.
POF Hospital (n= 76)
Wasim Uddin, Sohaib Ahmed and Tazaeen Kazmi.
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Ghulam Muhammad Mahar Medical College Teaching Hospital (n= 58)
Saleh Channa, Adeeqa Aman and Mouzam Shaikh.
DHQ Hospital Faisalabad (n = 47)
Tahir Rizvi and Amjad Hussain.
Rawalpindi Medical University Pakistan, DHQ Hospital Rawalpindi (n = 47)
Haider Zaigham Baqai and Zakawat Rasheed.
Shifa International Hospital (n = 41)
Abdus Khan and Adeela Irfan.
Allied Hospital Faisalabad Medical Unit III (n= 38)
Aamir Husain and Asifa Aslam.
Madinah Teaching Hospital Faisalabad (n= 34)
Khalid Yahya and Salman Azhar.
Liaquat National Hospital and Postgraduate Medical Centre (n = 33)
Mansoor Ul Haq and Adeel Afzal.
Services Institute of Medical Sciences/Services Hospital GI/Medical Unit II Lahore (n= 33)
Muhammad Imran and Iram Saeed.
Shaukat Khanum Memorial Hospital and Research Centre (n= 29)
Aasim Yusuf and Mariam Hassan.
Hayatabad Medical Complex (n= 25)
Mumtaz Marwat and Muhammad Ishfaq.
Sir Ganga Ram Hospital Medical Unit III (n = 20)
Tahir Bashir.
Liaquat University of Medical and Health Sciences Medical Unit II (n= 17)
Santosh Kumar.
DHQ Hospital, Narowal (n= 16)
Sajjad Yaqoob.
DHQ Hospital Khuzdar (n = 8)
Abdul Wahid.
Nigeria (n = 770)
University College Hospital Ibadan (n= 143)
Adegboyega Akere, Tinuola Fakoya, Temitope Oke and Edries Tejan.
National Hospital Abuja (n = 109)
Oluwole Olaomi, Olawale Badejo, Okafor Nnaemaka and Nancy Ukwu.
Obafemi Awolowo University Teaching Hospital, Ile-Ife (n = 99)
Olukayode Arowolo, Adewale Aderounmu and Funmilola Wuraola.
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University of Benin Teaching Hospital (n= 74)
Rose Ugiagbe, Alexander Atiri and Enadeghe Eghaghe.
Olabisi Onabanjo University Teaching Hospital (n= 49)
Adeleke Adekoya, Adedayo Oluyomi Tade and Olatunji Shonoiki.
University of Ilorin Teaching Hospital (n= 49)
Samuel Olatoke and Toafiq Raji.
Federal Medical Centre, Owerri (n= 46)
Christopher Ekwunife and Chigozirim Onyekpere.
Ahmadu Bello University Teaching Hospital (n = 40)
Adamu Ahmed and Daniyan Muhammad.
Lagos University Teaching Hospital (n= 37)
Emuobor Odeghe, Olufunmilayo Lesi and Azeberoje Osueni.
Aminu Kano Teaching Hospital (n= 25)
Adamu Samaila and Aminu Nahuche.
Ekiti State University Teaching Hospital (n= 24)
Akande Ajayi.
Irrua Specialist Teaching Hospital (n = 24)
Andrew Dongo.
University of Nigeria Teaching Hospital, Enugu (n= 18)
Uchenna Ijoma.
Federal Medical Centre, Abeokuta (n = 8)
Ademola Tolulope Adebanjo.
Lagos State University Teaching Hospital (n= 7)
Rufina Igetei.
University of Abuja Teaching Hospital (n = 7)
Monday Yilkudi.
Maitama District Hospital (n= 6)
Kehinde Osisanya.
Jos University Teaching Hospital (n= 3)
Edith Nonyelum Okeke.
Imo State University Teaching Hospital (n = 2)
Oguamanam Okezie Enwere.
Egypt (n = 709)
Kasr Al Aini Internal Medicine Hospital, Cairo University (n = 641)
Serag Esmat, Omar Ashoush, Mazen Naga, Fady Nagy, Mostafa Saiid and Ahmed Shaker.
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Mataria Teaching Hospital (n = 60)
Hussein Khamis, Ashraf Helmy and Saafan Saafan.
Badr Hospital, Helwan University (n = 8)
Mohammed Abdel Monem.
Malaysia (n = 464)
Hospital Tengku Ampuan Afzan (n= 123)
Jiffre Din, Khairul Azis, Muhyuddin Brukan and Sanjay Singh.
Hospital Universiti Sains Malaysia (n= 110)
Andee Zakaria, Shaik Farid, Nizam Hashim and Masykurin Mafauzy.
Hospital Sultanah Bahiyah (n = 71)
Wan Najmi, Nil Amri and Xin Yi.
Hospital Raja Permaisuri Bainun (n = 63)
Mohammad Hisyam, Elaine Ng and Zuhrirahimi Ramli.
Pulau Pinang General Hospital (n= 55)
Shyang Yee Lim, Kelvin Voon and Sir Young Yam.
Sungai Buloh Hospital (n = 42)
Mohammad Jahit and Lee Joon.
Georgia (n = 425)
High Technology Medical Centre, University Clinic (n = 364)
Besik Melikidze, Davit Kazaishvili, Tamar Gogichaishvili, Nino Grubelashvili and Baadur Mosidze.
Centre of Emergency Surgery and Traumatology (n = 61)
Gia Tomadze and Avto Megreladze.
Romania (n = 287)
Clinical Emergency Hospital Bucharest – SCUB Floreasca (n= 128)
Ruxandra Oprita, Dorina Pestroiu Calescu, Camèlia Chioncel and Andrei Ragea.
Colentina Clinical Hospital (n= 58)
Bogdan Mateescu, Bogdan Busuioc and Andrei Voiosu.
Municipal Emergency Hospital Moinesti (n = 45)
Adrian Cotirlet and Iulia Pintilie.
Central University Emergency Military Hospital, ‘Carol Davila’ University of
Medicine and Pharmacy, Bucharest (n= 38)
Mariana Jinga and Daniel Balaban.
Regional Institute of Gastroenterology and Hepatology ‘Prof Dr Octavian Fodor’ (n= 11)
Marcel Tanţ ău.
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University Hospital of Emergency Bucharest (n= 5)
Lucian Negreanu.
Emergency County Hospital Mures (n= 2)
Simona Bataga.
Nepal (n = 50)
Lifeline Hospital (n = 16)
Khushboo Priya.
Gandaki Medical College and Teaching Hospital (n= 12)
Shankar Baral.
Nepal Medical College and Teaching Hospital (n = 12)
Anuj KC.
Janaki Medical College (n = 4)
Vijay Sah.
National Medical College and Teaching Hospital (n= 4)
Vijay Yadav.
Lumbini Medical College and Teaching Hospital (n = 2)
Ajay Adhikaree.
Sudan (n = 40)
Ibn Sina Hospital (n= 40)
Abdelmounem Abdo and Dalia Ahmed.
Saudi Arabia (n = 19)
Prince Mohammed Bin Abdulaziz Hospital (n= 19)
Marzouqah Al Anazi and Areej Al Balkhi.
Ireland (n = 17)
Cork University Hospital (n= 17)
Conor Deasy.
Spain (n = 17)
Hospital Nuestra Señora del Prado (n = 9)
Joaquín Álvarez Gregori.
Torrecardenas Hospital (n= 8)
Helio Fornieles Pérez.
Albania (n = 16)
University Hospital Centre ‘Mother Teresa’ (n= 16)
Arben Beqiri.
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Papua New Guinea (n = 13)
Port Moresby General Hospital (n = 13)
Bobby Wellsh.
Australia (n = 11)
The Townsville Hospital (n = 11)
Luke Lawton.
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Appendix 2 Brief information sheet
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Appendix 3 Consent procedure overview
DOI: 10.3310/hta25580 Health Technology Assessment 2021 Vol. 25 No. 58
Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.




Patient competent to give valid
written consent considering the
urgency of the situation and
their mental state?
Relative or friend present and willing




Patient able to give agreement
for participation?
Two clinical personnel, one
independent of the trial, both
agree to enrol patient into the trial?
(Waiver of prior written consent)















• Patient given information sheet
• Consent form completed and
    signed by patient
• Obtain written consent from PrR
• Give patient information to level
    of capacity
• If patient regains capacity, obtain
    patient consent for continuation
    in the trial
• PeR given information sheet
• Consent form completed and
    signed by PeR
• Give patient information to level
    of capacity
• If patient regains capacity,
    obtain consent for continuation
    in the trial
If patient or representative is unable to
read or write:
• explain the trial in the presence of an
    independent witness
• patient/representative places mark
    (e.g. thumbprint) on consent form
• independent witness completes the
    consent form
• Give PeR brief information
    about the trial and obtain
    agreement for patient’s
    participation
• Obtain written consent from
    patient (if capacity returns)
    or from representative for
    continuation in the trial
• Give patient brief information
    about the trial and obtain
    agreement for participation
• Obtain written consent from
    patient (if capacity returns) 
    or from representative for
    continuation in the trial
• Write in medical records why
    written consent could not be
    obtained
• Obtain written consent from
    patient (if capacity returns) or
    from representative for
    continuation in the trial
PeR able to give valid consent
considering the urgency of the































Appendix 4 Entry form
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Appendix 5 Total number of randomisations




Africa 756 763 1519
Asia 2479 2474 4953
Europe, Australia and North America 2752 2772 5524
Caribbean, Central and South America 0 0 0
Oceania 7 6 13
Total 5994 6015 12,009
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Appendix 6 Outcome form
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Appendix 7 Adverse events between groups
Adverse event TXA group Placebo group Total
Abdominal distension 0 1 1
Abdominal pain 2 3 5
Abscess 1 1 2
Acute confusion state 3 1 4
Acute enterocolitis 1 0 1
Adenocarcinoma 0 1 1
Alcohol intoxication 1 0 1
Alcoholic withdrawal symptoms 1 2 3
Allergic reaction 5 6 11
Anaemia 5 13 18
Angina pectoris 2 0 2
Angiodysplasia 1 0 1
Appendicitis 1 0 1
Arterioenteric fistula 1 0 1
Ascites 2 4 6
Aspiration 0 1 1
Atrial fibrillation 0 2 2
Bowel infarction 0 1 1
Bowel perforation 0 1 1
Brain lesion 0 1 1
COPD exacerbation 3 2 5
Calculus biliary 1 0 1
Cardiac arrest 0 1 1
Cardiac failure congestive 0 3 3
Cellulitis 3 4 7
Cerebral infarction 1 0 1
Chemotherapy NOS 0 2 2
Chest pain 2 2 4
Cholangiocarcinoma 0 1 1
Cholangitis 1 0 1
Cholecystitis 0 1 1
Chronic venous insufficiency 0 1 1
Clostridium difficile infection 2 6 8
Coagulopathy 1 0 1
Colorectal cancer 0 1 1
Conjunctivitis 1 0 1
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Adverse event TXA group Placebo group Total
Constipation 5 3 8
Contusion 1 0 1
Crohn’s disease 0 1 1
Crystal arthropathy 0 1 1
Cyanosis 0 1 1
Deep-vein thrombosis 4 1 5
Dehydration 0 1 1
Delirium 1 2 3
Diarrhoea 3 2 5
Diverticular disease 3 1 4
Duodenal perforation 1 0 1
Dyspepsia 0 1 1
Embolus in foot 1 0 1
Encephalopathy 2 2 4
Enterocutaneous fistula 1 0 1
Epistaxis 1 1 2
Erythema 1 1 2
Fall 6 9 15
Febrile neutropenia 2 0 2
Fluid overload 1 1 2
Fluid retention 1 0 1
Fracture of unspecified intracapsular femur 0 1 1
Frailty 1 0 1
Gallbladder polyp 1 0 1
Gastric cancer 1 0 1
Gastric ulcer 1 0 1
Gastritis 1 4 5
Gastroenteritis 1 1 2
GI haemorrhage 66 80 146
Gout 3 1 4
Groin pain 1 0 1
Haematoma 1 0 1
Haematuria traumatic 0 1 1
Haemodilution 1 0 1
Haemorrhoids 2 2 4
Head injury 1 0 1
Heart failure 0 1 1
Hemicolectomy 0 1 1
Hepatic cirrhosis 6 3 9
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Adverse event TXA group Placebo group Total
Hepatic encephalopathy 0 1 1
Hepatitis 0 1 1
Hepatocellular carcinoma 0 1 1
Hepatorenal syndrome 1 0 1
Humerus fracture 0 1 1
Hydrocele 0 1 1
Hypernatraemia 0 1 1
Hypoglycaemia 2 2 4
Hypokalaemia 2 1 3
Hypomagnesaemia 1 0 1
Hyponatraemia 1 2 3
Hypotension 1 0 1
Hypoxia 0 1 1
Infected skin ulcer 0 1 1
International normalised ratio abnormal 1 0 1
Intestinal stoma leak 0 1 1
Ischaemic heart disease 0 1 1
Ischaemic hepatitis 0 1 1
Ischaemic stroke 3 3 6
Jaundice 0 1 1
Large bowel obstruction 1 0 1
Leg ischaemia 0 1 1
Liver abscess 0 1 1
Liver carcinoma ruptured 1 0 1
Liver cirrhosis 1 0 1
Lower respiratory tract infection 1 1 2
Lung cancer 1 0 1
Mallory–Weiss tear 0 1 1
Mastoid effusion 0 1 1
Meningioma 1 0 1
Multiorgan failure 2 0 2
Myocardial infarction 2 1 3
Nasogastric tube irritation 1 0 1
Necrotising otitis externa 0 1 1
Neuropathy peripheral 0 1 1
Obstructive jaundice 0 1 1
Oedema 1 3 4
Oesophageal cancer 1 1 2
Oesophageal candida 0 3 3
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Adverse event TXA group Placebo group Total
Oesophagitis 0 3 3
Overdose 1 1 2
Pain 1 0 1
Palpitations 1 0 1
Pancreatitis 1 0 1
Panic attack 1 0 1
Perforated gastric ulcer 1 0 1
Pericardial effusion 1 0 1
Peritonitis 4 0 4
Pharyngitis 1 0 1
Phlebitis 2 0 2
Pleural effusion 0 2 2
Pneumonia 9 3 12
Portal vein thrombosis 1 1 2
Postural hypotension 1 2 3
Pressure sore 1 1 2
Pulmonary embolism 3 3 6
Pulmonary haemorrhage 1 0 1
Pulmonary oedema 1 0 1
Pyelonephritis 0 1 1
Pyrexia 3 3 6
Rash 1 0 1
Refeeding syndrome 0 2 2
Renal failure 2 1 3
Respiratory infection 12 1 13
Seizure 3 1 4
Sepsis 6 7 13
Shingles 0 1 1
Shortness of breath 1 0 1
Small bowel obstruction 2 2 4
Staphylococcal bacteraemia 1 0 1
Stoma site bleeding 1 0 1
Suicidal ideation 0 1 1
Supraventricular tachycardia 0 1 1
Swollen lips 1 0 1
Syncope 1 1 2
Thoracic aneurysm, ruptured 0 1 1
Thrombocytopenia 1 1 2
Thrombosis 2 1 3
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Adverse event TXA group Placebo group Total
Transfusion reaction 0 1 1
Transient ischaemic attack 1 2 3
Type 2 diabetes mellitus 1 0 1
Upper GI haemorrhage 1 0 1
Urinary incontinence 0 1 1
Urinary retention 1 1 2
Urinary tract infection 12 12 24
Ventricular tachycardia 1 0 1
Vomiting 1 2 3
Total 273 281 554
COPD, chronic obstructive pulmonary disease; NOS, not otherwise specified.
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Appendix 8 Dissemination plan
Background
Gastrointestinal bleeding, from peptic ulcers, dilated gullet veins and cancer, is a common medical
emergency that causes hundreds of thousands of deaths worldwide. Patients can either vomit blood
or pass blood in the stools, and up to 10% of affected patients die. Some patients stop bleeding only to
start bleeding again a short time later, and these patients have particularly high death rates. Treatment
includes blood transfusion and emergency surgery to tie off the bleeding vessels.
Tranexamic acid reduces bleeding in surgery and reduces deaths from bleeding after serious injury and
childbirth, in both cases without increasing side effects. TXA is licensed for the treatment of GI bleeding.
Only a few small trials have looked at the effect of TXA in stomach bleeding but, when these trials were
added together, there appeared to be a large reduction in deaths with TXA. For many doctors, this evidence
was conclusive; indeed, many were so convinced that they refused to take part in the trial given that
this would mean that half of their patients would receive a placebo. However, doctors at LSHTM were
sceptical and decided to carry out a large international clinical trial.
The HALT-IT trial
The HALT-IT trial is a randomised, blinded, placebo-controlled trial in 12,009 patients with severe GI
bleeding. Patients were recruited from 164 hospitals across 15 countries. The aim was to assess the
effects of TXA in patients with GI bleeding. The primary outcome was death due to bleeding within
5 days of randomisation.
Objectives of dissemination
The results showed that TXA does not reduce deaths from stomach bleeding but increases the risk of
thromboembolic events (clots in the veins of the legs that can move to the lungs). There were also
more seizures with TXA. Rebleeding was similar in both groups.
Although it is often assumed that a treatment that works in one bleeding situation will probably work
in another, these results highlight the need for clinical trials that target specific causes of bleeding.
Stomach bleeding may respond differently, particularly in patients with underlying liver disease, who
may be more prone to side effects from unwanted clotting.
Given that TXA is already in use for the treatment of GI bleeding, these results have the potential to
change medical practice.
Help our collaborators to disseminate the results in their respective countries
Dissemination tools will be developed that collaborators can use for national and international audiences.
We need to upgrade our trial website and make sure that it hosts all of the trial dissemination materials
that can be downloaded and used locally. Dissemination tools for collaborating investigators will be
created so they can raise awareness about the trial results. Collaborating investigators will play a vital
role in disseminating the results to colleagues and patients in their countries.
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Specific outputs
1. Main publication of the trial results in The Lancet is expected on 20 June 2020.
2. Links to the publication will be made available in all applicable trial registers, the trial and
CTU websites.
3. A PowerPoint presentation of the results will be prepared and made available for use by doctors
and other health-care professionals.
4. Dissemination of results to patients will take place via the media and the trial website
(haltit.lshtm.ac.uk).
5. A lay result summary is being prepared for sharing with trial participants.
6. A social media strategy is being prepared. However, it is important to note that the trial results
are being published during the COVID-19 pandemic and this may limit the impact of our
dissemination plan.
7. Upgrade the trial website: make sure that it hosts trial-related materials that can be downloaded by
investigators and others and used for dissemination.
8. A podcast with the breakdown of the trial results and interview with Professor Ian Roberts will be
broadcasted at The Resus Room (@TheResusRoom).
9. Once all prespecified analyses are completed, totally anonymised data will be shared via the LSHTM
CTU data-sharing platform at freebird.lshtm.ac.uk. This will allow for maximum utilisation of the
data to improve patient care and advance medical knowledge. The trial protocol, statistical analysis
plan and trial publications will be freely available online.
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